cancer_type,TMB (FMOne mutation burden per MB),Neoantigen burden per MB,Immune phenotype,response_label,user_question,full_query
BLCA,18.0,4.68627451,excluded,NR,"I have a male patient with bladder urothelial carcinoma whose bladder biopsy shows specific mRNA TPM expression data and a tumor mutational burden of 18.0. Based on these findings, what is the likelihood of a favorable response to Atezolizumab?","I have a male patient with bladder urothelial carcinoma whose bladder biopsy shows specific mRNA TPM expression data and a tumor mutational burden of 18.0. Based on these findings, what is the likelihood of a favorable response to Atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/0257bb-ar-0257bbb.pkl. "
BLCA,1.0,0.31372549,desert,NR,"For a male patient with bladder urothelial carcinoma who has had mRNA TPM expression assessed from a bladder biopsy and exhibits a tumor mutational burden of 1.0, what is the likelihood that the patient will respond favorably to treatment with atezolizumab?","For a male patient with bladder urothelial carcinoma who has had mRNA TPM expression assessed from a bladder biopsy and exhibits a tumor mutational burden of 1.0, what is the likelihood that the patient will respond favorably to treatment with atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/025b45-ar-025b45c.pkl. "
BLCA,44.0,6.196078431,inflamed,NR,"I have a female patient with bladder urothelial carcinoma with mRNA TPM expression data obtained from a bladder biopsy and a tumor mutational burden of 44.0. Based on these molecular findings, what is the likelihood that she will respond to atezolizumab therapy?","I have a female patient with bladder urothelial carcinoma with mRNA TPM expression data obtained from a bladder biopsy and a tumor mutational burden of 44.0. Based on these molecular findings, what is the likelihood that she will respond to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/032c64-ar-032c642.pkl. "
BLCA,2.0,1.470588235,excluded,NR,"In a patient with bladder urothelial carcinoma who has undergone mRNA TPM expression profiling from a lymph node biopsy and exhibits a tumor mutational burden of 2.0, how might these findings inform the likelihood of a favorable response to atezolizumab therapy?","In a patient with bladder urothelial carcinoma who has undergone mRNA TPM expression profiling from a lymph node biopsy and exhibits a tumor mutational burden of 2.0, how might these findings inform the likelihood of a favorable response to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/0571f1-ar-0571f17.pkl. "
BLCA,8.0,,inflamed,R,"I have a male patient with bladder urothelial carcinoma whose tumor biopsy showed an mRNA TPM expression profile indicative of the tumor immune microenvironment and a tumor mutational burden of 8.0. Based on this information, what is the likelihood that the patient will respond favorably to atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma whose tumor biopsy showed an mRNA TPM expression profile indicative of the tumor immune microenvironment and a tumor mutational burden of 8.0. Based on this information, what is the likelihood that the patient will respond favorably to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/065890-ar-0658907.pkl. "
BLCA,6.0,0.921568627,,R,"I have a female patient with bladder urothelial carcinoma whose bladder biopsy showed mRNA TPM expression data for evaluating the tumor immune microenvironment, and she has a tumor mutational burden (TMB) of 6.0. Would this TMB level suggest that she is likely to respond favorably to treatment with atezolizumab?","I have a female patient with bladder urothelial carcinoma whose bladder biopsy showed mRNA TPM expression data for evaluating the tumor immune microenvironment, and she has a tumor mutational burden (TMB) of 6.0. Would this TMB level suggest that she is likely to respond favorably to treatment with atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/0684af-ar-0684af7.pkl. "
BLCA,11.0,0.745098039,excluded,R,"In a male patient with bladder urothelial carcinoma, a kidney biopsy was performed to assess the tumor immune microenvironment using mRNA TPM expression, and the tumor mutational burden is 11.0. Based on these biomarkers, would the patient be likely to respond favorably to atezolizumab therapy?","In a male patient with bladder urothelial carcinoma, a kidney biopsy was performed to assess the tumor immune microenvironment using mRNA TPM expression, and the tumor mutational burden is 11.0. Based on these biomarkers, would the patient be likely to respond favorably to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/075e03-ar-075e037.pkl. "
BLCA,18.0,2.117647059,excluded,R,"I am evaluating a male patient with bladder urothelial carcinoma who has an mRNA TPM expression profile from a bladder biopsy that reflects the tumor immune microenvironment. With a tumor mutational burden (TMB) of 18, is he likely to respond favorably to Atezolizumab therapy?","I am evaluating a male patient with bladder urothelial carcinoma who has an mRNA TPM expression profile from a bladder biopsy that reflects the tumor immune microenvironment. With a tumor mutational burden (TMB) of 18, is he likely to respond favorably to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/07a93a-ar-07a93a2.pkl. "
BLCA,,,excluded,NR,"I have a female patient with bladder urothelial carcinoma, and we obtained mRNA TPM expression data from her biopsy to assess the tumor immune microenvironment. However, her tumor mutational burden (TMB) is not available. Given this molecular profile, what is your assessment regarding her likely response to atezolizumab therapy?","I have a female patient with bladder urothelial carcinoma, and we obtained mRNA TPM expression data from her biopsy to assess the tumor immune microenvironment. However, her tumor mutational burden (TMB) is not available. Given this molecular profile, what is your assessment regarding her likely response to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/08cce2-ar-08cce2f.pkl. "
BLCA,,,inflamed,NR,"In a male patient with bladder urothelial carcinoma, mRNA TPM expression was evaluated from a nano-biopsy to characterize the tumor immune microenvironment, and the tumor mutational burden has been determined. Based on these molecular findings, what is the likelihood that the patient will respond to Atezolizumab therapy?","In a male patient with bladder urothelial carcinoma, mRNA TPM expression was evaluated from a nano-biopsy to characterize the tumor immune microenvironment, and the tumor mutational burden has been determined. Based on these molecular findings, what is the likelihood that the patient will respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/09c84e-ar-09c84ec.pkl. "
BLCA,2.0,0.215686275,,NR,"I have a male patient with bladder urothelial carcinoma whose tumor immune microenvironment was evaluated using mRNA TPM expression from a kidney biopsy. With a tumor mutational burden of 2.0, could you please advise on the likelihood of response to Atezolizumab?","I have a male patient with bladder urothelial carcinoma whose tumor immune microenvironment was evaluated using mRNA TPM expression from a kidney biopsy. With a tumor mutational burden of 2.0, could you please advise on the likelihood of response to Atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/0a0f2b-ar-0a0f2ba.pkl. "
BLCA,8.0,1.274509804,excluded,NR,"In a male patient with bladder urothelial carcinoma, whose bladder biopsy shows mRNA TPM expression analysis of the tumor immune microenvironment and a tumor mutational burden of 8.0, would you anticipate a favorable response to Atezolizumab therapy?","In a male patient with bladder urothelial carcinoma, whose bladder biopsy shows mRNA TPM expression analysis of the tumor immune microenvironment and a tumor mutational burden of 8.0, would you anticipate a favorable response to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/0a7c20-ar-0a7c209.pkl. "
BLCA,,,,NR,"I have a female patient with bladder urothelial carcinoma whose mRNA TPM expression, determined from a lymph node biopsy to evaluate the tumor immune microenvironment, is available, though her tumor mutational burden is reported as “nan.” Given these findings, is there sufficient evidence to suggest that she would respond favorably to atezolizumab therapy?","I have a female patient with bladder urothelial carcinoma whose mRNA TPM expression, determined from a lymph node biopsy to evaluate the tumor immune microenvironment, is available, though her tumor mutational burden is reported as “nan.” Given these findings, is there sufficient evidence to suggest that she would respond favorably to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/0bdb34-ar-0bdb342.pkl. "
BLCA,9.0,,excluded,NR,"I have a male patient with bladder urothelial carcinoma whose mRNA TPM expression was measured from a ureter biopsy to evaluate the tumor immune microenvironment, and his tumor mutational burden is 9.0. Based on these findings, is he likely to respond favorably to atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma whose mRNA TPM expression was measured from a ureter biopsy to evaluate the tumor immune microenvironment, and his tumor mutational burden is 9.0. Based on these findings, is he likely to respond favorably to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/0ce9c9-ar-0ce9c98.pkl. "
BLCA,4.0,0.137254902,desert,NR,"In a female patient with bladder urothelial carcinoma, whose bladder biopsy shows quantified mRNA TPM expression levels to assess the tumor immune microenvironment and a tumor mutational burden of 4.0, is she likely to benefit from Atezolizumab therapy?","In a female patient with bladder urothelial carcinoma, whose bladder biopsy shows quantified mRNA TPM expression levels to assess the tumor immune microenvironment and a tumor mutational burden of 4.0, is she likely to benefit from Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/0d855c-ar-0d855cf.pkl. "
BLCA,32.0,4.098039216,excluded,NR,"I have a male patient with bladder urothelial carcinoma who underwent a ureter biopsy for mRNA TPM expression analysis to assess the tumor immune microenvironment, and his tumor mutational burden is 32.0. Based on these findings, how likely is he to respond to Atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma who underwent a ureter biopsy for mRNA TPM expression analysis to assess the tumor immune microenvironment, and his tumor mutational burden is 32.0. Based on these findings, how likely is he to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/0f956e-ar-0f956e7.pkl. "
BLCA,21.0,3.529411765,desert,NR,"A male patient with bladder urothelial carcinoma has recently undergone a bladder biopsy, from which mRNA expression and tumor immune microenvironment data were obtained. With a tumor mutational burden measured at 21.0, could you please advise if Atezolizumab is an appropriate treatment option for this patient?","A male patient with bladder urothelial carcinoma has recently undergone a bladder biopsy, from which mRNA expression and tumor immune microenvironment data were obtained. With a tumor mutational burden measured at 21.0, could you please advise if Atezolizumab is an appropriate treatment option for this patient?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/110501-ar-110501d.pkl. "
BLCA,10.0,1.078431373,inflamed,NR,"We have a male patient with bladder urothelial carcinoma whose tumor was evaluated using mRNA TPM expression from a kidney biopsy to assess the immune microenvironment, and his tumor mutational burden is 10.0. Given these parameters, what is the likelihood that he will respond to atezolizumab therapy?","We have a male patient with bladder urothelial carcinoma whose tumor was evaluated using mRNA TPM expression from a kidney biopsy to assess the immune microenvironment, and his tumor mutational burden is 10.0. Given these parameters, what is the likelihood that he will respond to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/12502d-ar-12502d9.pkl. "
BLCA,38.0,6.68627451,desert,R,"In a male patient with bladder urothelial carcinoma, whose tumor biopsy revealed specific mRNA TPM expression patterns to assess the immune microenvironment and a tumor mutational burden of 38.0, is there evidence indicating a favorable response to atezolizumab therapy?","In a male patient with bladder urothelial carcinoma, whose tumor biopsy revealed specific mRNA TPM expression patterns to assess the immune microenvironment and a tumor mutational burden of 38.0, is there evidence indicating a favorable response to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/149386-ar-1493861.pkl. "
BLCA,7.0,0.568627451,excluded,R,"For a female patient with bladder urothelial carcinoma, whose tumor immune microenvironment was assessed via mRNA TPM expression from a bladder biopsy and who has a tumor mutational burden of 7.0, would you expect a favorable response to atezolizumab therapy?","For a female patient with bladder urothelial carcinoma, whose tumor immune microenvironment was assessed via mRNA TPM expression from a bladder biopsy and who has a tumor mutational burden of 7.0, would you expect a favorable response to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/14df63-ar-14df63a.pkl. "
BLCA,5.0,0.274509804,excluded,NR,"A male patient with bladder urothelial carcinoma has had a bladder biopsy showing mRNA TPM expression data of the tumor immune microenvironment and a tumor mutational burden of 5.0. Based on these findings, what is the likelihood that he will respond to Atezolizumab therapy?","A male patient with bladder urothelial carcinoma has had a bladder biopsy showing mRNA TPM expression data of the tumor immune microenvironment and a tumor mutational burden of 5.0. Based on these findings, what is the likelihood that he will respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/166a41-ar-166a419.pkl. "
BLCA,15.0,,desert,NR,"I have a male patient with bladder urothelial carcinoma confirmed by biopsy. The tumor's mRNA expression profile (TPM) was evaluated to characterize the immune microenvironment, and the tumor mutational burden is 15.0. Based on these findings, would you expect this patient to respond favorably to Atezolizumab?","I have a male patient with bladder urothelial carcinoma confirmed by biopsy. The tumor's mRNA expression profile (TPM) was evaluated to characterize the immune microenvironment, and the tumor mutational burden is 15.0. Based on these findings, would you expect this patient to respond favorably to Atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/180398-ar-1803982.pkl. "
BLCA,,0.215686275,excluded,NR,"I have a male patient with bladder urothelial carcinoma. A kidney biopsy was performed to measure mRNA TPM expression as part of an evaluation of the tumor immune microenvironment, but the tumor mutational burden is currently unknown. Considering these factors, what is the likelihood that the patient will respond to atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma. A kidney biopsy was performed to measure mRNA TPM expression as part of an evaluation of the tumor immune microenvironment, but the tumor mutational burden is currently unknown. Considering these factors, what is the likelihood that the patient will respond to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/181b63-ar-181b638.pkl. "
BLCA,,,,NR,"I have a male patient with bladder urothelial carcinoma (BLCA) whose mRNA TPM expression was analyzed from a lung biopsy to assess the tumor immune microenvironment. The tumor mutational burden data is not available. Given this clinical context, is it reasonable to expect a favorable response to Atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma (BLCA) whose mRNA TPM expression was analyzed from a lung biopsy to assess the tumor immune microenvironment. The tumor mutational burden data is not available. Given this clinical context, is it reasonable to expect a favorable response to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/187e05-ar-187e056.pkl. "
BLCA,18.0,2.039215686,excluded,NR,"In a male patient with bladder urothelial carcinoma, mRNA TPM expression analysis from a bladder biopsy was conducted to evaluate the tumor immune microenvironment, and the tumor mutational burden is 18.0. Given these findings, would you consider this patient likely to benefit from atezolizumab therapy?","In a male patient with bladder urothelial carcinoma, mRNA TPM expression analysis from a bladder biopsy was conducted to evaluate the tumor immune microenvironment, and the tumor mutational burden is 18.0. Given these findings, would you consider this patient likely to benefit from atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/18a4da-ar-18a4dab.pkl. "
BLCA,7.0,0.392156863,inflamed,NR,"In a male patient with bladder urothelial carcinoma, mRNA TPM expression was analyzed from a ureter biopsy to evaluate the tumor immune microenvironment. Given a tumor mutational burden of 7.0, what is the likelihood that the patient will respond to Atezolizumab therapy?","In a male patient with bladder urothelial carcinoma, mRNA TPM expression was analyzed from a ureter biopsy to evaluate the tumor immune microenvironment. Given a tumor mutational burden of 7.0, what is the likelihood that the patient will respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/18b935-ar-18b9351.pkl. "
BLCA,19.0,1.803921569,,NR,"Given a patient with bladder urothelial carcinoma whose bladder biopsy shows a specific mRNA TPM expression profile indicating the tumor immune microenvironment and a tumor mutational burden of 19.0, how likely is it that the patient will respond to atezolizumab therapy?","Given a patient with bladder urothelial carcinoma whose bladder biopsy shows a specific mRNA TPM expression profile indicating the tumor immune microenvironment and a tumor mutational burden of 19.0, how likely is it that the patient will respond to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/18bc10-ar-18bc107.pkl. "
BLCA,5.0,0.470588235,excluded,NR,"I have a male patient with bladder urothelial carcinoma who underwent a bladder biopsy for mRNA TPM expression profiling to evaluate the tumor immune microenvironment, and his tumor mutational burden is 5.0. Based on these findings, how likely is he to respond to atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma who underwent a bladder biopsy for mRNA TPM expression profiling to evaluate the tumor immune microenvironment, and his tumor mutational burden is 5.0. Based on these findings, how likely is he to respond to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/18be5b-ar-18be5b3.pkl. "
BLCA,5.0,0.431372549,excluded,NR,"A male patient with bladder urothelial carcinoma has undergone a bladder biopsy for mRNA TPM expression analysis to assess the tumor immune microenvironment and has a reported tumor mutational burden (TMB) of 5.0. Based on these factors, what is the likelihood that the patient will respond to atezolizumab therapy?","A male patient with bladder urothelial carcinoma has undergone a bladder biopsy for mRNA TPM expression analysis to assess the tumor immune microenvironment and has a reported tumor mutational burden (TMB) of 5.0. Based on these factors, what is the likelihood that the patient will respond to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/19fec8-ar-19fec8f.pkl. "
BLCA,8.0,1.176470588,excluded,NR,"In a patient with bladder urothelial carcinoma whose bladder biopsy showed specific mRNA TPM expression profiles indicative of the tumor immune microenvironment and a tumor mutational burden of 8.0, would treatment with Atezolizumab be expected to yield a favorable response?","In a patient with bladder urothelial carcinoma whose bladder biopsy showed specific mRNA TPM expression profiles indicative of the tumor immune microenvironment and a tumor mutational burden of 8.0, would treatment with Atezolizumab be expected to yield a favorable response?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/1a87df-ar-1a87df7.pkl. "
BLCA,13.0,0.294117647,desert,NR,"In a female patient with bladder urothelial carcinoma, where mRNA TPM expression from a ureter biopsy has been used to assess the tumor immune microenvironment and the tumor mutational burden is 13.0, would she be expected to respond favorably to treatment with atezolizumab?","In a female patient with bladder urothelial carcinoma, where mRNA TPM expression from a ureter biopsy has been used to assess the tumor immune microenvironment and the tumor mutational burden is 13.0, would she be expected to respond favorably to treatment with atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/1ab1b2-ar-1ab1b28.pkl. "
BLCA,16.0,1.862745098,excluded,R,"I have a male patient with bladder urothelial carcinoma whose tumor mutational burden is 16.0. Additionally, mRNA TPM expression data was obtained from a kidney biopsy to evaluate the tumor immune microenvironment. Based on these findings, how likely is he to respond to Atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma whose tumor mutational burden is 16.0. Additionally, mRNA TPM expression data was obtained from a kidney biopsy to evaluate the tumor immune microenvironment. Based on these findings, how likely is he to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/1abf01-ar-1abf01d.pkl. "
BLCA,2.0,0.647058824,excluded,NR,"I have a male patient with bladder urothelial carcinoma, and we assessed the tumor immune microenvironment using mRNA TPM expression from a kidney biopsy. With a tumor mutational burden of 2.0, how likely is the patient to respond to atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma, and we assessed the tumor immune microenvironment using mRNA TPM expression from a kidney biopsy. With a tumor mutational burden of 2.0, how likely is the patient to respond to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/1ac4e3-ar-1ac4e3d.pkl. "
BLCA,,,excluded,NR,"For a female patient with bladder urothelial carcinoma who underwent mRNA TPM expression analysis from a bladder biopsy and has a reported tumor mutational burden of ""nan,"" how likely is she to respond to Atezolizumab therapy?","For a female patient with bladder urothelial carcinoma who underwent mRNA TPM expression analysis from a bladder biopsy and has a reported tumor mutational burden of ""nan,"" how likely is she to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/1c0ecf-ar-1c0ecfb.pkl. "
BLCA,7.0,0.549019608,excluded,NR,For my male patient with bladder urothelial carcinoma—whose mRNA TPM expression profile was obtained from a bladder biopsy to evaluate the tumor immune microenvironment and who has a TMB of 7.0—would initiating treatment with atezolizumab likely result in a favorable response?,For my male patient with bladder urothelial carcinoma—whose mRNA TPM expression profile was obtained from a bladder biopsy to evaluate the tumor immune microenvironment and who has a TMB of 7.0—would initiating treatment with atezolizumab likely result in a favorable response?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/1c8b08-ar-1c8b086.pkl. 
BLCA,20.0,4.019607843,desert,NR,"In a male patient with bladder urothelial carcinoma (BLCA) whose mRNA TPM expression was evaluated from a bladder biopsy to assess the tumor immune microenvironment, and with a tumor mutational burden (TMB) of 20.0, is there evidence to suggest that he is likely to respond to Atezolizumab therapy?","In a male patient with bladder urothelial carcinoma (BLCA) whose mRNA TPM expression was evaluated from a bladder biopsy to assess the tumor immune microenvironment, and with a tumor mutational burden (TMB) of 20.0, is there evidence to suggest that he is likely to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/1dda30-ar-1dda30f.pkl. "
BLCA,5.0,1.431372549,inflamed,NR,"In a female patient with bladder urothelial carcinoma, the tumor's immune microenvironment was assessed using mRNA TPM expression from a bladder biopsy, and the tumor mutational burden is 5.0. Given these factors, how likely is the patient to respond to Atezolizumab therapy?","In a female patient with bladder urothelial carcinoma, the tumor's immune microenvironment was assessed using mRNA TPM expression from a bladder biopsy, and the tumor mutational burden is 5.0. Given these factors, how likely is the patient to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/1e9c4d-ar-1e9c4d1.pkl. "
BLCA,38.0,4.509803922,inflamed,R,"I am evaluating a male patient with bladder urothelial carcinoma. A recent biopsy provided mRNA TPM expression data to assess the tumor immune microenvironment, and the tumor mutational burden is notably high at 38.0. Based on these findings, how likely is the patient to respond to Atezolizumab therapy?","I am evaluating a male patient with bladder urothelial carcinoma. A recent biopsy provided mRNA TPM expression data to assess the tumor immune microenvironment, and the tumor mutational burden is notably high at 38.0. Based on these findings, how likely is the patient to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/1f66db-ar-1f66db5.pkl. "
BLCA,6.0,0.549019608,desert,NR,"For a male patient with bladder urothelial carcinoma (BLCA) whose tumor microenvironment was evaluated via mRNA TPM expression from a kidney biopsy and who has a tumor mutational burden (TMB) of 6.0, how likely is he to respond to Atezolizumab therapy?","For a male patient with bladder urothelial carcinoma (BLCA) whose tumor microenvironment was evaluated via mRNA TPM expression from a kidney biopsy and who has a tumor mutational burden (TMB) of 6.0, how likely is he to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/1f83eb-ar-1f83ebd.pkl. "
BLCA,8.0,1.235294118,inflamed,NR,"I have a male patient with bladder urothelial carcinoma. A biopsy revealed mRNA TPM expression levels were evaluated to characterize the tumor immune microenvironment, and the tumor mutational burden was measured at 8.0. Would these findings suggest that the patient is likely to respond to Atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma. A biopsy revealed mRNA TPM expression levels were evaluated to characterize the tumor immune microenvironment, and the tumor mutational burden was measured at 8.0. Would these findings suggest that the patient is likely to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/1fa6bc-ar-1fa6bcb.pkl. "
BLCA,13.0,2.392156863,inflamed,R,"I have a male patient with bladder urothelial carcinoma whose tumor mutational burden is 13.0, and mRNA TPM expression has been measured from a bladder biopsy to assess the tumor immune microenvironment. Given these findings, is he likely to respond to atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma whose tumor mutational burden is 13.0, and mRNA TPM expression has been measured from a bladder biopsy to assess the tumor immune microenvironment. Given these findings, is he likely to respond to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/203dcf-ar-203dcf1.pkl. "
BLCA,5.0,0.294117647,excluded,NR,"I have a male patient with bladder urothelial carcinoma whose tumor mRNA expression profile was obtained from a kidney biopsy to assess the immune microenvironment. The patient’s tumor mutational burden is 5.0. Based on this information, how likely is it that he will respond to Atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma whose tumor mRNA expression profile was obtained from a kidney biopsy to assess the immune microenvironment. The patient’s tumor mutational burden is 5.0. Based on this information, how likely is it that he will respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/2070b4-ar-2070b41.pkl. "
BLCA,5.0,0.235294118,desert,NR,"We have a female patient with bladder urothelial carcinoma whose bladder biopsy mRNA TPM expression was analyzed to assess the tumor immune microenvironment, and her tumor mutational burden is 5.0 mutations per megabase. Based on these factors, how likely is she to respond to Atezolizumab therapy?","We have a female patient with bladder urothelial carcinoma whose bladder biopsy mRNA TPM expression was analyzed to assess the tumor immune microenvironment, and her tumor mutational burden is 5.0 mutations per megabase. Based on these factors, how likely is she to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/230959-ar-2309593.pkl. "
BLCA,5.0,0.333333333,excluded,NR,"In a female patient with bladder urothelial carcinoma who has undergone mRNA TPM expression profiling from a kidney biopsy to assess the tumor immune microenvironment and has a tumor mutational burden of 5.0, how likely is she to respond to atezolizumab therapy?","In a female patient with bladder urothelial carcinoma who has undergone mRNA TPM expression profiling from a kidney biopsy to assess the tumor immune microenvironment and has a tumor mutational burden of 5.0, how likely is she to respond to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/23aa15-ar-23aa15d.pkl. "
BLCA,,1.823529412,desert,R,"I have a male patient with bladder urothelial carcinoma. We analyzed mRNA TPM expression from a separate biopsy to evaluate the tumor immune microenvironment, and the tumor mutational burden (TMB) is reported as 'nan.' Given these findings, what is the likelihood that the patient will respond to Atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma. We analyzed mRNA TPM expression from a separate biopsy to evaluate the tumor immune microenvironment, and the tumor mutational burden (TMB) is reported as 'nan.' Given these findings, what is the likelihood that the patient will respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/25510f-ar-25510f3.pkl. "
BLCA,12.0,1.529411765,inflamed,R,"I have a female patient with bladder urothelial carcinoma whose lymph node biopsy showed mRNA TPM expression for assessment of the tumor immune microenvironment, and the tumor mutational burden is 12.0. Based on these findings, is Atezolizumab likely to be effective for her treatment?","I have a female patient with bladder urothelial carcinoma whose lymph node biopsy showed mRNA TPM expression for assessment of the tumor immune microenvironment, and the tumor mutational burden is 12.0. Based on these findings, is Atezolizumab likely to be effective for her treatment?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/2570ff-ar-2570ff4.pkl. "
BLCA,1.0,0.274509804,excluded,NR,"My male patient with bladder urothelial carcinoma has a tumor mutational burden of 1.0, and we recently assessed the tumor immune microenvironment using mRNA TPM expression from a bladder biopsy. Given these findings, how likely is he to respond to treatment with atezolizumab?","My male patient with bladder urothelial carcinoma has a tumor mutational burden of 1.0, and we recently assessed the tumor immune microenvironment using mRNA TPM expression from a bladder biopsy. Given these findings, how likely is he to respond to treatment with atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/26104d-ar-26104d5.pkl. "
BLCA,6.0,0.431372549,excluded,NR,"I am evaluating a male patient with bladder urothelial carcinoma. The tumor's immune microenvironment was assessed via mRNA TPM expression profiling from a biopsy, and the tumor mutational burden is 6.0. Based on these results, is he likely to respond to Atezolizumab therapy?","I am evaluating a male patient with bladder urothelial carcinoma. The tumor's immune microenvironment was assessed via mRNA TPM expression profiling from a biopsy, and the tumor mutational burden is 6.0. Based on these results, is he likely to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/262422-ar-2624229.pkl. "
BLCA,8.0,0.745098039,excluded,R,"In a female patient with bladder urothelial carcinoma, mRNA TPM expression analysis from a bladder biopsy was performed to evaluate the tumor immune microenvironment, and the tumor mutational burden is 8.0 mutations/Mb. Based on these findings, would you expect a favorable response to Atezolizumab therapy?","In a female patient with bladder urothelial carcinoma, mRNA TPM expression analysis from a bladder biopsy was performed to evaluate the tumor immune microenvironment, and the tumor mutational burden is 8.0 mutations/Mb. Based on these findings, would you expect a favorable response to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/27299a-ar-27299ae.pkl. "
BLCA,6.0,0.568627451,inflamed,NR,"For a patient diagnosed with bladder urothelial carcinoma in whom mRNA TPM expression was measured from a kidney biopsy to evaluate the tumor immune microenvironment and who has a tumor mutational burden of 6.0, what is the likelihood that Atezolizumab therapy will be effective?","For a patient diagnosed with bladder urothelial carcinoma in whom mRNA TPM expression was measured from a kidney biopsy to evaluate the tumor immune microenvironment and who has a tumor mutational burden of 6.0, what is the likelihood that Atezolizumab therapy will be effective?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/286870-ar-2868703.pkl. "
BLCA,22.0,,desert,NR,"I have a male patient with bladder urothelial carcinoma who underwent a bladder biopsy, with mRNA TPM expression used to assess the tumor immune microenvironment, and his tumor mutational burden is 22. Would these factors suggest that he is likely to respond to Atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma who underwent a bladder biopsy, with mRNA TPM expression used to assess the tumor immune microenvironment, and his tumor mutational burden is 22. Would these factors suggest that he is likely to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/28e603-ar-28e6031.pkl. "
BLCA,1.0,,excluded,NR,"Given a patient with bladder urothelial carcinoma who has an mRNA TPM expression profile from a bladder biopsy and a low tumor mutational burden of 1.0, is it likely that the patient will respond to Atezolizumab therapy?","Given a patient with bladder urothelial carcinoma who has an mRNA TPM expression profile from a bladder biopsy and a low tumor mutational burden of 1.0, is it likely that the patient will respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/297c03-ar-297c030.pkl. "
BLCA,,0.490196078,desert,NR,"For our female patient with bladder urothelial carcinoma, whose tumor immune microenvironment was evaluated using mRNA TPM expression from a ureter biopsy, and with an indeterminate tumor mutational burden, is she likely to respond to Atezolizumab?","For our female patient with bladder urothelial carcinoma, whose tumor immune microenvironment was evaluated using mRNA TPM expression from a ureter biopsy, and with an indeterminate tumor mutational burden, is she likely to respond to Atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/29da92-ar-29da928.pkl. "
BLCA,2.0,0.156862745,desert,NR,"I’m evaluating a male patient with bladder urothelial carcinoma who underwent a kidney biopsy for mRNA TPM expression analysis to assess his tumor immune microenvironment. Given his tumor mutational burden of 2.0, is he likely to respond to Atezolizumab therapy?","I’m evaluating a male patient with bladder urothelial carcinoma who underwent a kidney biopsy for mRNA TPM expression analysis to assess his tumor immune microenvironment. Given his tumor mutational burden of 2.0, is he likely to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/2b672f-ar-2b672f4.pkl. "
BLCA,11.0,1.294117647,excluded,NR,"In a patient with bladder urothelial carcinoma, mRNA TPM expression profiling from a bladder biopsy indicated a specific tumor immune microenvironment, and the tumor mutational burden is 11.0 mutations per megabase. Given these findings, what is the likelihood that the patient will respond to Atezolizumab?","In a patient with bladder urothelial carcinoma, mRNA TPM expression profiling from a bladder biopsy indicated a specific tumor immune microenvironment, and the tumor mutational burden is 11.0 mutations per megabase. Given these findings, what is the likelihood that the patient will respond to Atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/2bba8c-ar-2bba8cb.pkl. "
BLCA,9.0,0.431372549,desert,NR,"I have a male patient with bladder urothelial carcinoma. A bladder biopsy was performed to evaluate the tumor immune microenvironment, including mRNA TPM expression levels, and the tumor mutational burden was determined to be 9.0. Based on these factors, how likely is the patient to respond to Atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma. A bladder biopsy was performed to evaluate the tumor immune microenvironment, including mRNA TPM expression levels, and the tumor mutational burden was determined to be 9.0. Based on these factors, how likely is the patient to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/2c9586-ar-2c95861.pkl. "
BLCA,,,inflamed,NR,"In a male patient with bladder urothelial carcinoma whose tumor immune microenvironment was evaluated using mRNA TPM expression from a kidney biopsy—and with the tumor mutational burden reported as ""nan""—would you expect a favorable clinical response to Atezolizumab therapy?","In a male patient with bladder urothelial carcinoma whose tumor immune microenvironment was evaluated using mRNA TPM expression from a kidney biopsy—and with the tumor mutational burden reported as ""nan""—would you expect a favorable clinical response to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/2dc3f0-ar-2dc3f04.pkl. "
BLCA,14.0,2.705882353,excluded,NR,"I have a male patient with bladder urothelial carcinoma whose tumor immune microenvironment was assessed via mRNA TPM expression from a kidney biopsy. With a tumor mutational burden of 14.0, would he be likely to respond to Atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma whose tumor immune microenvironment was assessed via mRNA TPM expression from a kidney biopsy. With a tumor mutational burden of 14.0, would he be likely to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/2e7aa8-ar-2e7aa8f.pkl. "
BLCA,18.0,1.764705882,,R,"I am assessing a male patient with bladder urothelial carcinoma who has a tumor mutational burden of 18.0. mRNA TPM expression analysis from a bladder biopsy was performed to evaluate the tumor's immune microenvironment. Based on these findings, how likely is the patient to benefit from Atezolizumab therapy?","I am assessing a male patient with bladder urothelial carcinoma who has a tumor mutational burden of 18.0. mRNA TPM expression analysis from a bladder biopsy was performed to evaluate the tumor's immune microenvironment. Based on these findings, how likely is the patient to benefit from Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/2e9ac0-ar-2e9ac0b.pkl. "
BLCA,13.0,1.137254902,inflamed,R,"For a male patient with bladder urothelial carcinoma, mRNA TPM expression from a bladder biopsy has been used to evaluate the tumor immune microenvironment, and his tumor mutational burden is 13.0. Given this information, how likely is he to respond to Atezolizumab therapy?","For a male patient with bladder urothelial carcinoma, mRNA TPM expression from a bladder biopsy has been used to evaluate the tumor immune microenvironment, and his tumor mutational burden is 13.0. Given this information, how likely is he to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/2eb07d-ar-2eb07de.pkl. "
BLCA,8.0,0.450980392,excluded,NR,"For a female patient with bladder urothelial carcinoma, mRNA TPM expression analysis from a bladder biopsy has been performed to evaluate the tumor immune microenvironment, and the tumor mutational burden is 8.0. Based on these parameters, what is the likelihood of a positive response to Atezolizumab therapy?","For a female patient with bladder urothelial carcinoma, mRNA TPM expression analysis from a bladder biopsy has been performed to evaluate the tumor immune microenvironment, and the tumor mutational burden is 8.0. Based on these parameters, what is the likelihood of a positive response to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/2f2289-ar-2f22893.pkl. "
BLCA,6.0,,excluded,R,"I have a female patient with bladder urothelial carcinoma whose tumor biopsy revealed mRNA TPM expression data for assessing the immune microenvironment, and the tumor mutational burden is 6.0 mutations per megabase. Considering these factors, how likely is it that she will respond favorably to Atezolizumab therapy?","I have a female patient with bladder urothelial carcinoma whose tumor biopsy revealed mRNA TPM expression data for assessing the immune microenvironment, and the tumor mutational burden is 6.0 mutations per megabase. Considering these factors, how likely is it that she will respond favorably to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/30b5c6-ar-30b5c6c.pkl. "
BLCA,,,excluded,NR,"I have a patient with bladder urothelial carcinoma who underwent a bladder biopsy with mRNA TPM expression analysis to assess the tumor immune microenvironment. The tumor mutational burden (TMB) is reported as “nan.” Given this information, what is the likelihood that the patient will respond to Atezolizumab therapy?","I have a patient with bladder urothelial carcinoma who underwent a bladder biopsy with mRNA TPM expression analysis to assess the tumor immune microenvironment. The tumor mutational burden (TMB) is reported as “nan.” Given this information, what is the likelihood that the patient will respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/30cf07-ar-30cf07d.pkl. "
BLCA,23.0,4.235294118,inflamed,R,"In a patient with bladder urothelial carcinoma who has a tumor mutational burden of 23, and whose tumor immune microenvironment was characterized by mRNA expression analysis from a bladder biopsy, would treatment with Atezolizumab likely result in a favorable therapeutic response?","In a patient with bladder urothelial carcinoma who has a tumor mutational burden of 23, and whose tumor immune microenvironment was characterized by mRNA expression analysis from a bladder biopsy, would treatment with Atezolizumab likely result in a favorable therapeutic response?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/31d917-ar-31d9176.pkl. "
BLCA,,0.705882353,,NR,"For a female patient with bladder urothelial carcinoma, whose mRNA TPM expression was assessed from a lymph node biopsy to evaluate the tumor immune microenvironment and whose tumor mutational burden is reported as 'nan', would the patient likely respond to atezolizumab therapy?","For a female patient with bladder urothelial carcinoma, whose mRNA TPM expression was assessed from a lymph node biopsy to evaluate the tumor immune microenvironment and whose tumor mutational burden is reported as 'nan', would the patient likely respond to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/31f41d-ar-31f41dd.pkl. "
BLCA,2.0,,,NR,"For a male patient with bladder urothelial carcinoma who has undergone a lymph node biopsy with mRNA TPM expression profiling to assess the tumor immune microenvironment and a tumor mutational burden of 2.0, how likely is it that he will respond to Atezolizumab therapy?","For a male patient with bladder urothelial carcinoma who has undergone a lymph node biopsy with mRNA TPM expression profiling to assess the tumor immune microenvironment and a tumor mutational burden of 2.0, how likely is it that he will respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/3330c0-ar-3330c03.pkl. "
BLCA,,,,NR,"In a patient with bladder urothelial carcinoma, we evaluated the tumor immune microenvironment using mRNA TPM expression from a bladder biopsy, but the tumor mutational burden is not available. Considering treatment with atezolizumab, what is the likelihood of a favorable response based on these molecular findings?","In a patient with bladder urothelial carcinoma, we evaluated the tumor immune microenvironment using mRNA TPM expression from a bladder biopsy, but the tumor mutational burden is not available. Considering treatment with atezolizumab, what is the likelihood of a favorable response based on these molecular findings?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/34430e-ar-34430ef.pkl. "
BLCA,7.0,0.333333333,excluded,NR,"Given a male patient with bladder urothelial carcinoma who has a tumor mutational burden of 7.0 and mRNA TPM expression data from a bladder biopsy assessing the tumor immune microenvironment, how likely is a favorable response to treatment with Atezolizumab?","Given a male patient with bladder urothelial carcinoma who has a tumor mutational burden of 7.0 and mRNA TPM expression data from a bladder biopsy assessing the tumor immune microenvironment, how likely is a favorable response to treatment with Atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/36851b-ar-36851bc.pkl. "
BLCA,1.0,0.607843137,inflamed,NR,"For a patient with bladder urothelial carcinoma whose biopsy shows quantified mRNA TPM expression and a tumor mutational burden of 1.0, how likely is it that treatment with Atezolizumab would be effective?","For a patient with bladder urothelial carcinoma whose biopsy shows quantified mRNA TPM expression and a tumor mutational burden of 1.0, how likely is it that treatment with Atezolizumab would be effective?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/36a922-ar-36a9225.pkl. "
BLCA,7.0,0.352941176,excluded,NR,"I have a male patient with bladder urothelial carcinoma whose tumor mutational burden is 7.0. His mRNA TPM expression was measured from a ureter biopsy to evaluate the tumor immune microenvironment. Given these factors, how likely is the patient to respond to atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma whose tumor mutational burden is 7.0. His mRNA TPM expression was measured from a ureter biopsy to evaluate the tumor immune microenvironment. Given these factors, how likely is the patient to respond to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/36d873-ar-36d8739.pkl. "
BLCA,5.0,,excluded,NR,"We have a patient with bladder urothelial carcinoma whose bladder biopsy revealed mRNA TPM expression data assessing the tumor immune microenvironment, and the tumor mutational burden is 5.0. Considering these findings, how likely is it that the patient will respond favorably to atezolizumab?","We have a patient with bladder urothelial carcinoma whose bladder biopsy revealed mRNA TPM expression data assessing the tumor immune microenvironment, and the tumor mutational burden is 5.0. Considering these findings, how likely is it that the patient will respond favorably to atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/3894ac-ar-3894ac3.pkl. "
BLCA,6.0,,excluded,NR,"For a male patient with bladder urothelial carcinoma, whose biopsy mRNA TPM expression data reflects the tumor immune microenvironment and who has a tumor mutational burden of 6.0, how likely is it that he will respond to Atezolizumab therapy?","For a male patient with bladder urothelial carcinoma, whose biopsy mRNA TPM expression data reflects the tumor immune microenvironment and who has a tumor mutational burden of 6.0, how likely is it that he will respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/39eb94-ar-39eb94f.pkl. "
BLCA,,,,NR,"In a male patient with bladder urothelial carcinoma, mRNA TPM expression was measured from a lung biopsy to evaluate the tumor immune microenvironment, but the tumor mutational burden data is unavailable. Given these factors, how likely is the patient to respond to Atezolizumab therapy?","In a male patient with bladder urothelial carcinoma, mRNA TPM expression was measured from a lung biopsy to evaluate the tumor immune microenvironment, but the tumor mutational burden data is unavailable. Given these factors, how likely is the patient to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/3a1c96-ar-3a1c963.pkl. "
BLCA,2.0,0.176470588,excluded,NR,"In a male patient with bladder urothelial carcinoma who underwent a lymph node biopsy for mRNA TPM expression analysis of the tumor immune microenvironment and has a tumor mutational burden of 2.0, how likely is it that he will respond to Atezolizumab therapy?","In a male patient with bladder urothelial carcinoma who underwent a lymph node biopsy for mRNA TPM expression analysis of the tumor immune microenvironment and has a tumor mutational burden of 2.0, how likely is it that he will respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/3b1066-ar-3b1066e.pkl. "
BLCA,44.0,5.823529412,inflamed,R,"For a male patient with bladder urothelial carcinoma whose mRNA TPM expression from a biopsy indicates the profile of the tumor immune microenvironment and with a high tumor mutational burden of 44.0, would you expect a favorable response to Atezolizumab therapy?","For a male patient with bladder urothelial carcinoma whose mRNA TPM expression from a biopsy indicates the profile of the tumor immune microenvironment and with a high tumor mutational burden of 44.0, would you expect a favorable response to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/3b15b4-ar-3b15b4c.pkl. "
BLCA,15.0,2.235294118,excluded,NR,"In a male patient with bladder urothelial carcinoma who underwent a kidney biopsy for mRNA TPM expression profiling of the tumor immune microenvironment, the tumor mutational burden is 15.0. Could these findings indicate a favorable response to Atezolizumab therapy?","In a male patient with bladder urothelial carcinoma who underwent a kidney biopsy for mRNA TPM expression profiling of the tumor immune microenvironment, the tumor mutational burden is 15.0. Could these findings indicate a favorable response to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/3cb94b-ar-3cb94b0.pkl. "
BLCA,17.0,1.411764706,excluded,R,"For a patient with bladder urothelial carcinoma who has a tumor mutational burden of 17.0 and mRNA TPM expression data obtained from a lymph node biopsy, how likely is it that they would respond to treatment with Atezolizumab given the characteristics of their tumor immune microenvironment?","For a patient with bladder urothelial carcinoma who has a tumor mutational burden of 17.0 and mRNA TPM expression data obtained from a lymph node biopsy, how likely is it that they would respond to treatment with Atezolizumab given the characteristics of their tumor immune microenvironment?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/3e04eb-ar-3e04eb9.pkl. "
BLCA,11.0,1.215686275,desert,NR,"I have a male patient with bladder urothelial carcinoma (BLCA) whose tumor profile—including mRNA TPM expression from a kidney biopsy and a tumor mutational burden (TMB) of 11.0—has been evaluated. Based on these findings, how likely is it that the patient will respond to Atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma (BLCA) whose tumor profile—including mRNA TPM expression from a kidney biopsy and a tumor mutational burden (TMB) of 11.0—has been evaluated. Based on these findings, how likely is it that the patient will respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/3e8baf-ar-3e8baff.pkl. "
BLCA,,,desert,NR,"A male patient with bladder urothelial carcinoma has mRNA TPM expression data obtained from a bladder biopsy to evaluate the tumor immune microenvironment, but his tumor mutational burden (TMB) is not available. Based on this information, what is the likelihood that he will respond favorably to Atezolizumab therapy?","A male patient with bladder urothelial carcinoma has mRNA TPM expression data obtained from a bladder biopsy to evaluate the tumor immune microenvironment, but his tumor mutational burden (TMB) is not available. Based on this information, what is the likelihood that he will respond favorably to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/3ee5dc-ar-3ee5dcd.pkl. "
BLCA,,0.431372549,excluded,NR,"In a male patient with bladder urothelial carcinoma, mRNA TPM expression from a bladder biopsy was used to assess the tumor immune microenvironment, but the tumor mutational burden (TMB) is not available. Given this information, what is the likelihood of a favorable response to Atezolizumab?","In a male patient with bladder urothelial carcinoma, mRNA TPM expression from a bladder biopsy was used to assess the tumor immune microenvironment, but the tumor mutational burden (TMB) is not available. Given this information, what is the likelihood of a favorable response to Atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/415f36-ar-415f36a.pkl. "
BLCA,12.0,0.392156863,desert,NR,"In a male patient with bladder urothelial carcinoma, mRNA expression profiling (TPM) from a biopsy has been completed to assess the tumor immune microenvironment, and the tumor mutational burden is 12.0. Given these factors, is the patient likely to benefit from Atezolizumab therapy?","In a male patient with bladder urothelial carcinoma, mRNA expression profiling (TPM) from a biopsy has been completed to assess the tumor immune microenvironment, and the tumor mutational burden is 12.0. Given these factors, is the patient likely to benefit from Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/4305ab-ar-4305ab9.pkl. "
BLCA,6.0,0.921568627,excluded,NR,"In a patient with bladder urothelial carcinoma whose tumor immune microenvironment was evaluated via mRNA TPM expression from a bladder biopsy and with a tumor mutational burden of 6.0, would you expect a favorable response to Atezolizumab therapy?","In a patient with bladder urothelial carcinoma whose tumor immune microenvironment was evaluated via mRNA TPM expression from a bladder biopsy and with a tumor mutational burden of 6.0, would you expect a favorable response to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/4501e4-ar-4501e41.pkl. "
BLCA,5.0,1.392156863,inflamed,NR,"I have a male patient with bladder urothelial carcinoma whose mRNA TPM expression was measured from a bladder biopsy to evaluate the tumor immune microenvironment, and his tumor mutational burden is 5.0. Given these findings, how likely is it that he will respond to atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma whose mRNA TPM expression was measured from a bladder biopsy to evaluate the tumor immune microenvironment, and his tumor mutational burden is 5.0. Given these findings, how likely is it that he will respond to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/45c8e6-ar-45c8e64.pkl. "
BLCA,8.0,,desert,NR,"In a patient with bladder urothelial carcinoma who has undergone nanobiopsy for mRNA TPM expression profiling to assess the tumor immune microenvironment and presents with a tumor mutational burden of 8.0, what is the likelihood of a favorable response to Atezolizumab therapy?","In a patient with bladder urothelial carcinoma who has undergone nanobiopsy for mRNA TPM expression profiling to assess the tumor immune microenvironment and presents with a tumor mutational burden of 8.0, what is the likelihood of a favorable response to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/468a9e-ar-468a9e1.pkl. "
BLCA,8.0,0.803921569,inflamed,NR,"In a male patient with bladder urothelial carcinoma, mRNA TPM expression data from a bladder biopsy and a tumor mutational burden (TMB) of 8.0 have been obtained. Based on these findings, how likely is it that the patient will respond favorably to Atezolizumab therapy?","In a male patient with bladder urothelial carcinoma, mRNA TPM expression data from a bladder biopsy and a tumor mutational burden (TMB) of 8.0 have been obtained. Based on these findings, how likely is it that the patient will respond favorably to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/47fc46-ar-47fc46c.pkl. "
BLCA,0.0,0.607843137,excluded,NR,"In a male patient with bladder urothelial carcinoma (BLCA), whose bladder biopsy shows mRNA TPM expression profiling results and a tumor mutational burden (TMB) of 0.0, how likely is it that treatment with Atezolizumab will be effective?","In a male patient with bladder urothelial carcinoma (BLCA), whose bladder biopsy shows mRNA TPM expression profiling results and a tumor mutational burden (TMB) of 0.0, how likely is it that treatment with Atezolizumab will be effective?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/49d487-ar-49d4875.pkl. "
BLCA,5.0,1.450980392,excluded,NR,"I have a male patient with bladder urothelial carcinoma (BLCA) whose tumor immune microenvironment was assessed via mRNA TPM expression from a kidney biopsy, and the tumor mutational burden is 5.0. Based on these findings, is he likely to benefit from Atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma (BLCA) whose tumor immune microenvironment was assessed via mRNA TPM expression from a kidney biopsy, and the tumor mutational burden is 5.0. Based on these findings, is he likely to benefit from Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/49f9b2-ar-49f9b2e.pkl. "
BLCA,6.0,,desert,NR,"In a male patient with bladder urothelial carcinoma, mRNA TPM expression was evaluated from a kidney biopsy to assess the tumor immune microenvironment, and a tumor mutational burden of 6.0 was recorded. Based on these findings, what is the anticipated likelihood of a favorable response to Atezolizumab therapy?","In a male patient with bladder urothelial carcinoma, mRNA TPM expression was evaluated from a kidney biopsy to assess the tumor immune microenvironment, and a tumor mutational burden of 6.0 was recorded. Based on these findings, what is the anticipated likelihood of a favorable response to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/4b0175-ar-4b0175e.pkl. "
BLCA,,,excluded,NR,"For a female patient with bladder urothelial carcinoma, we obtained mRNA TPM expression data from a kidney biopsy to assess the tumor immune microenvironment, and the tumor mutational burden value is not available. Considering these factors, how likely is she to benefit from treatment with atezolizumab?","For a female patient with bladder urothelial carcinoma, we obtained mRNA TPM expression data from a kidney biopsy to assess the tumor immune microenvironment, and the tumor mutational burden value is not available. Considering these factors, how likely is she to benefit from treatment with atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/4b7ea0-ar-4b7ea01.pkl. "
BLCA,59.0,11.68627451,excluded,R,"In a male patient with bladder urothelial carcinoma whose ureter biopsy demonstrated mRNA TPM expression indicative of the tumor immune microenvironment and a tumor mutational burden of 59.0, would these factors suggest a favorable response to atezolizumab therapy?","In a male patient with bladder urothelial carcinoma whose ureter biopsy demonstrated mRNA TPM expression indicative of the tumor immune microenvironment and a tumor mutational burden of 59.0, would these factors suggest a favorable response to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/4caabd-ar-4caabd6.pkl. "
BLCA,13.0,0.31372549,desert,NR,"In a male patient with bladder urothelial carcinoma (BLCA) who underwent a kidney biopsy for mRNA TPM expression analysis of the tumor immune microenvironment and has a tumor mutational burden (TMB) of 13.0, how likely is he to respond to Atezolizumab therapy?","In a male patient with bladder urothelial carcinoma (BLCA) who underwent a kidney biopsy for mRNA TPM expression analysis of the tumor immune microenvironment and has a tumor mutational burden (TMB) of 13.0, how likely is he to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/523468-ar-5234688.pkl. "
BLCA,12.0,0.745098039,excluded,NR,"I have a female patient with bladder urothelial carcinoma whose mRNA TPM expression was assessed from a ureter biopsy to evaluate the tumor immune microenvironment, and her tumor mutational burden is 12.0. Given these factors, is she likely to respond favorably to Atezolizumab treatment?","I have a female patient with bladder urothelial carcinoma whose mRNA TPM expression was assessed from a ureter biopsy to evaluate the tumor immune microenvironment, and her tumor mutational burden is 12.0. Given these factors, is she likely to respond favorably to Atezolizumab treatment?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/52500c-ar-52500ca.pkl. "
BLCA,4.0,0.254901961,,NR,"I have a patient with bladder urothelial carcinoma whose tumor immune microenvironment was evaluated using mRNA TPM expression from a lymph node biopsy, and the tumor exhibits a mutational burden of 4.0. Given these findings, how likely is the patient to respond to atezolizumab therapy?","I have a patient with bladder urothelial carcinoma whose tumor immune microenvironment was evaluated using mRNA TPM expression from a lymph node biopsy, and the tumor exhibits a mutational burden of 4.0. Given these findings, how likely is the patient to respond to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/52e3fa-ar-52e3fa3.pkl. "
BLCA,11.0,1.823529412,desert,R,"In a male patient with bladder urothelial carcinoma, tumor immune microenvironment analysis via mRNA TPM expression and a tumor mutational burden of 11.0 were obtained from the bladder biopsy. Based on these factors, is treatment with atezolizumab likely to be effective?","In a male patient with bladder urothelial carcinoma, tumor immune microenvironment analysis via mRNA TPM expression and a tumor mutational burden of 11.0 were obtained from the bladder biopsy. Based on these factors, is treatment with atezolizumab likely to be effective?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/548551-ar-548551e.pkl. "
BLCA,5.0,,desert,NR,"I have a male patient with bladder urothelial carcinoma who recently underwent a bladder biopsy to assess mRNA TPM expression for evaluation of the tumor immune microenvironment. The tumor exhibits a mutational burden of 5.0. Given these findings, what is the likelihood that he will benefit from Atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma who recently underwent a bladder biopsy to assess mRNA TPM expression for evaluation of the tumor immune microenvironment. The tumor exhibits a mutational burden of 5.0. Given these findings, what is the likelihood that he will benefit from Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/54e58f-ar-54e58f1.pkl. "
BLCA,,,,NR,"I have a female patient with bladder urothelial carcinoma. We assessed her tumor immune microenvironment using mRNA TPM expression from a kidney biopsy, but her tumor mutational burden data is not available. Given these findings, how likely is she to benefit from treatment with Atezolizumab?","I have a female patient with bladder urothelial carcinoma. We assessed her tumor immune microenvironment using mRNA TPM expression from a kidney biopsy, but her tumor mutational burden data is not available. Given these findings, how likely is she to benefit from treatment with Atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/553c3c-ar-553c3c3.pkl. "
BLCA,5.0,,excluded,NR,"I have a male patient with bladder urothelial carcinoma whose mRNA TPM expression from a ureter biopsy has been analyzed to evaluate the tumor immune microenvironment. The patient's tumor mutational burden is 5.0. Given these findings, what is the likelihood of a positive response to Atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma whose mRNA TPM expression from a ureter biopsy has been analyzed to evaluate the tumor immune microenvironment. The patient's tumor mutational burden is 5.0. Given these findings, what is the likelihood of a positive response to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/557dde-ar-557dde1.pkl. "
BLCA,19.0,0.647058824,inflamed,R,"I am managing a male patient with bladder urothelial carcinoma whose mRNA TPM expression was evaluated from an alternative biopsy to assess the tumor immune microenvironment, and his tumor mutational burden is 19.0. Based on these findings, would you anticipate a favorable response to Atezolizumab therapy?","I am managing a male patient with bladder urothelial carcinoma whose mRNA TPM expression was evaluated from an alternative biopsy to assess the tumor immune microenvironment, and his tumor mutational burden is 19.0. Based on these findings, would you anticipate a favorable response to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/560f23-ar-560f23d.pkl. "
BLCA,,0.607843137,,NR,"In a male patient with bladder urothelial carcinoma, a bladder biopsy was analyzed for mRNA TPM expression to evaluate the tumor immune microenvironment, and the tumor mutational burden is reported as “NaN.” Based on these results, what is the likelihood that the patient will respond to Atezolizumab therapy?","In a male patient with bladder urothelial carcinoma, a bladder biopsy was analyzed for mRNA TPM expression to evaluate the tumor immune microenvironment, and the tumor mutational burden is reported as “NaN.” Based on these results, what is the likelihood that the patient will respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/563d62-ar-563d623.pkl. "
BLCA,,,,NR,"In a female patient diagnosed with bladder urothelial carcinoma, mRNA TPM expression profiling from her bladder biopsy was used to characterize the tumor immune microenvironment, but the tumor mutational burden (TMB) could not be determined. Given these findings, what is the likelihood that she will respond to Atezolizumab therapy?","In a female patient diagnosed with bladder urothelial carcinoma, mRNA TPM expression profiling from her bladder biopsy was used to characterize the tumor immune microenvironment, but the tumor mutational burden (TMB) could not be determined. Given these findings, what is the likelihood that she will respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/568ce1-ar-568ce16.pkl. "
BLCA,33.0,5.509803922,excluded,R,"In a male patient with bladder urothelial carcinoma who has an elevated tumor mutational burden of 33.0 and whose tumor immune microenvironment was evaluated via mRNA TPM expression from a kidney biopsy, is there evidence to suggest that he will respond favorably to atezolizumab therapy?","In a male patient with bladder urothelial carcinoma who has an elevated tumor mutational burden of 33.0 and whose tumor immune microenvironment was evaluated via mRNA TPM expression from a kidney biopsy, is there evidence to suggest that he will respond favorably to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/572f19-ar-572f197.pkl. "
BLCA,32.0,,excluded,R,"In a male patient with bladder urothelial carcinoma, an mRNA TPM analysis was performed on a separate biopsy to assess the tumor immune microenvironment, and the tumor mutational burden is 32. Given these factors, how likely is it that the patient will respond to atezolizumab therapy?","In a male patient with bladder urothelial carcinoma, an mRNA TPM analysis was performed on a separate biopsy to assess the tumor immune microenvironment, and the tumor mutational burden is 32. Given these factors, how likely is it that the patient will respond to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/5767dd-ar-5767dd7.pkl. "
BLCA,2.0,0.333333333,desert,R,"I have a male patient with bladder urothelial carcinoma whose bladder biopsy shows mRNA TPM expression data evaluating the tumor immune microenvironment, and his tumor mutational burden is 2.0. Based on these findings, is he likely to respond to Atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma whose bladder biopsy shows mRNA TPM expression data evaluating the tumor immune microenvironment, and his tumor mutational burden is 2.0. Based on these findings, is he likely to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/58e783-ar-58e7832.pkl. "
BLCA,14.0,,excluded,NR,"In a male patient with bladder urothelial carcinoma, mRNA TPM expression from a bladder biopsy was analyzed to evaluate the tumor immune microenvironment, and the tumor exhibits a mutational burden of 14.0. Given these findings, how likely is the patient to respond favorably to atezolizumab therapy?","In a male patient with bladder urothelial carcinoma, mRNA TPM expression from a bladder biopsy was analyzed to evaluate the tumor immune microenvironment, and the tumor exhibits a mutational burden of 14.0. Given these findings, how likely is the patient to respond favorably to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/59f392-ar-59f3928.pkl. "
BLCA,,,,NR,"I have a male patient with bladder urothelial carcinoma whose tumor immune microenvironment was assessed via mRNA TPM expression from a nan biopsy, and the tumor mutational burden is reported as nan. Given these findings, how likely is he to respond to atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma whose tumor immune microenvironment was assessed via mRNA TPM expression from a nan biopsy, and the tumor mutational burden is reported as nan. Given these findings, how likely is he to respond to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/59fda9-ar-59fda90.pkl. "
BLCA,9.0,1.333333333,desert,NR,"In a male patient with bladder urothelial carcinoma, a bladder biopsy revealed mRNA TPM expression related to the tumor immune microenvironment, and the tumor mutational burden is 9.0. Considering the use of Atezolizumab, what is the likelihood of a favorable response based on these findings?","In a male patient with bladder urothelial carcinoma, a bladder biopsy revealed mRNA TPM expression related to the tumor immune microenvironment, and the tumor mutational burden is 9.0. Considering the use of Atezolizumab, what is the likelihood of a favorable response based on these findings?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/5a2347-ar-5a2347c.pkl. "
BLCA,12.0,,,NR,"For a female patient with bladder urothelial carcinoma who underwent a ureter biopsy for mRNA TPM profiling of the tumor immune microenvironment and has a tumor mutational burden of 12.0, how likely is it that she will respond to atezolizumab therapy?","For a female patient with bladder urothelial carcinoma who underwent a ureter biopsy for mRNA TPM profiling of the tumor immune microenvironment and has a tumor mutational burden of 12.0, how likely is it that she will respond to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/5b57e4-ar-5b57e47.pkl. "
BLCA,,,excluded,NR,"In a male patient with bladder urothelial carcinoma who underwent a bladder biopsy for mRNA TPM expression analysis of the tumor immune microenvironment, and whose tumor mutational burden is reported as 'nan', how likely is he to respond to treatment with Atezolizumab?","In a male patient with bladder urothelial carcinoma who underwent a bladder biopsy for mRNA TPM expression analysis of the tumor immune microenvironment, and whose tumor mutational burden is reported as 'nan', how likely is he to respond to treatment with Atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/5c139c-ar-5c139c5.pkl. "
BLCA,11.0,0.411764706,desert,NR,"I have a male patient with bladder urothelial carcinoma whose tumor mRNA TPM expression was assessed via biopsy to evaluate the immune microenvironment. With a tumor mutational burden of 11.0, how likely is this patient to respond to Atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma whose tumor mRNA TPM expression was assessed via biopsy to evaluate the immune microenvironment. With a tumor mutational burden of 11.0, how likely is this patient to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/5cc2d9-ar-5cc2d90.pkl. "
BLCA,10.0,1.215686275,,NR,"In a male patient with bladder urothelial carcinoma, mRNA TPM expression from a liver biopsy has been used to characterize the tumor immune microenvironment, and the tumor mutation burden is 10. Considering these biomarkers, would you expect this patient to respond favorably to atezolizumab therapy?","In a male patient with bladder urothelial carcinoma, mRNA TPM expression from a liver biopsy has been used to characterize the tumor immune microenvironment, and the tumor mutation burden is 10. Considering these biomarkers, would you expect this patient to respond favorably to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/5cfa16-ar-5cfa169.pkl. "
BLCA,12.0,,,NR,"We have a male patient with bladder urothelial carcinoma who has a tumor mutational burden of 12.0 and mRNA TPM expression data from a bladder biopsy assessing the tumor immune microenvironment. Based on these findings, is he likely to respond to atezolizumab therapy?","We have a male patient with bladder urothelial carcinoma who has a tumor mutational burden of 12.0 and mRNA TPM expression data from a bladder biopsy assessing the tumor immune microenvironment. Based on these findings, is he likely to respond to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/5d1dfd-ar-5d1dfd5.pkl. "
BLCA,13.0,1.411764706,desert,NR,"In a female patient with bladder urothelial carcinoma, a bladder biopsy analysis showed mRNA TPM expression to evaluate the tumor immune microenvironment, and her tumor mutational burden is 13.0. Based on these findings, how likely is she to respond to Atezolizumab therapy?","In a female patient with bladder urothelial carcinoma, a bladder biopsy analysis showed mRNA TPM expression to evaluate the tumor immune microenvironment, and her tumor mutational burden is 13.0. Based on these findings, how likely is she to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/5d989c-ar-5d989c8.pkl. "
BLCA,6.0,0.823529412,excluded,NR,"In a male patient with bladder urothelial carcinoma, mRNA TPM expression was measured from a kidney biopsy to evaluate the tumor's immune microenvironment, and the tumor mutational burden is 6.0. Based on these findings, how likely is this patient to benefit from atezolizumab therapy?","In a male patient with bladder urothelial carcinoma, mRNA TPM expression was measured from a kidney biopsy to evaluate the tumor's immune microenvironment, and the tumor mutational burden is 6.0. Based on these findings, how likely is this patient to benefit from atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/5e3bae-ar-5e3bae0.pkl. "
BLCA,21.0,3.823529412,inflamed,NR,"I have a patient with bladder urothelial carcinoma whose tumor immune microenvironment was evaluated using mRNA TPM expression from a ureter biopsy, and the tumor has a mutational burden of 21.0. Based on these findings, how likely is this patient to respond to treatment with atezolizumab?","I have a patient with bladder urothelial carcinoma whose tumor immune microenvironment was evaluated using mRNA TPM expression from a ureter biopsy, and the tumor has a mutational burden of 21.0. Based on these findings, how likely is this patient to respond to treatment with atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/5fe7a8-ar-5fe7a81.pkl. "
BLCA,14.0,,inflamed,R,"Given a male patient with bladder urothelial carcinoma, whose bladder biopsy showed mRNA TPM expression for tumor immune microenvironment assessment and a tumor mutational burden of 14, how likely is he to respond to Atezolizumab therapy?","Given a male patient with bladder urothelial carcinoma, whose bladder biopsy showed mRNA TPM expression for tumor immune microenvironment assessment and a tumor mutational burden of 14, how likely is he to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/6083aa-ar-6083aac.pkl. "
BLCA,9.0,1.803921569,desert,R,"In a male patient with bladder urothelial carcinoma, whose bladder biopsy analysis showed specific mRNA TPM expression to assess the tumor immune microenvironment and who has a tumor mutational burden of 9.0, is treatment with atezolizumab likely to be effective?","In a male patient with bladder urothelial carcinoma, whose bladder biopsy analysis showed specific mRNA TPM expression to assess the tumor immune microenvironment and who has a tumor mutational burden of 9.0, is treatment with atezolizumab likely to be effective?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/6157c8-ar-6157c8f.pkl. "
BLCA,27.0,5.882352941,inflamed,NR,"I am managing a male patient with bladder urothelial carcinoma (BLCA) and have obtained mRNA TPM expression data from a bladder biopsy to evaluate the tumor immune microenvironment. The patient’s tumor mutational burden is 27.0. Based on these findings, how likely is the patient to respond to Atezolizumab therapy?","I am managing a male patient with bladder urothelial carcinoma (BLCA) and have obtained mRNA TPM expression data from a bladder biopsy to evaluate the tumor immune microenvironment. The patient’s tumor mutational burden is 27.0. Based on these findings, how likely is the patient to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/61b9d4-ar-61b9d4d.pkl. "
BLCA,,,desert,NR,"I have a female patient with bladder urothelial carcinoma whose lymph node biopsy was analyzed for mRNA TPM expression to evaluate the tumor immune microenvironment. The tumor mutational burden (TMB) is not available. Given this information, would you expect the patient to respond to Atezolizumab therapy?","I have a female patient with bladder urothelial carcinoma whose lymph node biopsy was analyzed for mRNA TPM expression to evaluate the tumor immune microenvironment. The tumor mutational burden (TMB) is not available. Given this information, would you expect the patient to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/61baf9-ar-61baf91.pkl. "
BLCA,5.0,0.784313725,,NR,"For a female patient with bladder urothelial carcinoma, who underwent mRNA TPM expression profiling from a kidney biopsy to evaluate the tumor immune microenvironment and has a tumor mutational burden of 5.0, what is the likelihood that she will respond favorably to Atezolizumab therapy?","For a female patient with bladder urothelial carcinoma, who underwent mRNA TPM expression profiling from a kidney biopsy to evaluate the tumor immune microenvironment and has a tumor mutational burden of 5.0, what is the likelihood that she will respond favorably to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/62fb13-ar-62fb138.pkl. "
BLCA,,0.156862745,,NR,"I have a male patient with bladder urothelial carcinoma whose bladder biopsy revealed mRNA TPM expression data to assess the tumor immune microenvironment, and his tumor mutational burden is reported as nan. Considering these molecular characteristics, how likely is he to benefit from treatment with Atezolizumab?","I have a male patient with bladder urothelial carcinoma whose bladder biopsy revealed mRNA TPM expression data to assess the tumor immune microenvironment, and his tumor mutational burden is reported as nan. Considering these molecular characteristics, how likely is he to benefit from treatment with Atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/63405b-ar-63405b0.pkl. "
BLCA,14.0,0.980392157,desert,NR,"In a male patient with bladder urothelial carcinoma, mRNA TPM expression profiling of a bladder biopsy was performed to characterize the tumor immune microenvironment. With a tumor mutational burden of 14.0, what is the likelihood of a favorable response to Atezolizumab therapy?","In a male patient with bladder urothelial carcinoma, mRNA TPM expression profiling of a bladder biopsy was performed to characterize the tumor immune microenvironment. With a tumor mutational burden of 14.0, what is the likelihood of a favorable response to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/63b218-ar-63b2189.pkl. "
BLCA,4.0,0.294117647,excluded,NR,"I have a patient with bladder urothelial carcinoma whose bladder biopsy revealed mRNA TPM expression profiling of the tumor immune microenvironment, and the tumor mutational burden is 4.0. Given these findings, what is the likelihood of a favorable response to Atezolizumab therapy?","I have a patient with bladder urothelial carcinoma whose bladder biopsy revealed mRNA TPM expression profiling of the tumor immune microenvironment, and the tumor mutational burden is 4.0. Given these findings, what is the likelihood of a favorable response to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/65afda-ar-65afda2.pkl. "
BLCA,5.0,0.490196078,inflamed,NR,"I'm evaluating a male patient with bladder urothelial carcinoma whose tumor biopsy recently underwent mRNA TPM expression profiling to assess the immune microenvironment. Given that his tumor mutational burden is 5.0, can we expect a favorable response to atezolizumab therapy?","I'm evaluating a male patient with bladder urothelial carcinoma whose tumor biopsy recently underwent mRNA TPM expression profiling to assess the immune microenvironment. Given that his tumor mutational burden is 5.0, can we expect a favorable response to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/6662f5-ar-6662f51.pkl. "
BLCA,15.0,2.68627451,excluded,R,"How likely is a positive response to atezolizumab in a female patient with bladder urothelial carcinoma who has a tumor mutational burden of 15.0, based on mRNA TPM expression profiling of her bladder biopsy to assess the tumor immune microenvironment?","How likely is a positive response to atezolizumab in a female patient with bladder urothelial carcinoma who has a tumor mutational burden of 15.0, based on mRNA TPM expression profiling of her bladder biopsy to assess the tumor immune microenvironment?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/670649-ar-670649e.pkl. "
BLCA,13.0,1.254901961,desert,NR,"In a male patient with bladder urothelial carcinoma, mRNA TPM expression measured from a bladder biopsy was used to assess the tumor immune microenvironment, and the tumor mutational burden is 13.0. Based on these findings, is it likely that the patient will benefit from Atezolizumab therapy?","In a male patient with bladder urothelial carcinoma, mRNA TPM expression measured from a bladder biopsy was used to assess the tumor immune microenvironment, and the tumor mutational burden is 13.0. Based on these findings, is it likely that the patient will benefit from Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/675a12-ar-675a12a.pkl. "
BLCA,14.0,2.549019608,inflamed,NR,"In a female patient with bladder urothelial carcinoma whose tumor exhibits a TMB of 14.0 and whose bladder biopsy has been assessed for mRNA TPM expression to evaluate the tumor immune microenvironment, is there evidence to suggest that Atezolizumab would be an effective treatment option?","In a female patient with bladder urothelial carcinoma whose tumor exhibits a TMB of 14.0 and whose bladder biopsy has been assessed for mRNA TPM expression to evaluate the tumor immune microenvironment, is there evidence to suggest that Atezolizumab would be an effective treatment option?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/6780ed-ar-6780ed4.pkl. "
BLCA,17.0,1.117647059,desert,NR,"I have a male patient with bladder urothelial carcinoma whose bladder biopsy yielded mRNA TPM expression data to evaluate the tumor immune microenvironment. His tumor mutational burden is 17.0, and I am considering treatment with Atezolizumab. Based on these findings, what is the likelihood that he will respond to this therapy?","I have a male patient with bladder urothelial carcinoma whose bladder biopsy yielded mRNA TPM expression data to evaluate the tumor immune microenvironment. His tumor mutational burden is 17.0, and I am considering treatment with Atezolizumab. Based on these findings, what is the likelihood that he will respond to this therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/6792d6-ar-6792d6e.pkl. "
BLCA,7.0,1.862745098,excluded,R,"I have a male patient diagnosed with bladder urothelial carcinoma. His tumor biopsy was analyzed for mRNA TPM expression to evaluate the immune microenvironment, and the tumor mutational burden (TMB) was determined to be 7.0 mutations/Mb. Based on these findings, can we expect him to respond favorably to Atezolizumab therapy?","I have a male patient diagnosed with bladder urothelial carcinoma. His tumor biopsy was analyzed for mRNA TPM expression to evaluate the immune microenvironment, and the tumor mutational burden (TMB) was determined to be 7.0 mutations/Mb. Based on these findings, can we expect him to respond favorably to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/681e4b-ar-681e4bf.pkl. "
BLCA,5.0,1.176470588,,NR,"For a male patient with bladder urothelial carcinoma, whose tumor immune microenvironment was characterized by mRNA TPM expression profiling from a bladder biopsy and who has a tumor mutational burden of 5.0, would Atezolizumab be expected to be an effective treatment option?","For a male patient with bladder urothelial carcinoma, whose tumor immune microenvironment was characterized by mRNA TPM expression profiling from a bladder biopsy and who has a tumor mutational burden of 5.0, would Atezolizumab be expected to be an effective treatment option?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/6964a6-ar-6964a6d.pkl. "
BLCA,20.0,1.039215686,desert,R,"For a male patient with bladder urothelial carcinoma, mRNA TPM expression from a lung biopsy was used to characterize the tumor immune microenvironment, and the tumor mutational burden is 20.0. Based on these factors, would treatment with Atezolizumab be expected to be effective?","For a male patient with bladder urothelial carcinoma, mRNA TPM expression from a lung biopsy was used to characterize the tumor immune microenvironment, and the tumor mutational burden is 20.0. Based on these factors, would treatment with Atezolizumab be expected to be effective?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/6cb230-ar-6cb230f.pkl. "
BLCA,3.0,0.960784314,inflamed,NR,"I have a male patient with bladder urothelial carcinoma. His tumor mRNA expression was quantified using TPM from a bladder biopsy to assess the tumor immune microenvironment, and his tumor mutational burden is 3.0. Considering these factors, would he be a likely candidate for a favorable response to Atezolizumab?","I have a male patient with bladder urothelial carcinoma. His tumor mRNA expression was quantified using TPM from a bladder biopsy to assess the tumor immune microenvironment, and his tumor mutational burden is 3.0. Considering these factors, would he be a likely candidate for a favorable response to Atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/6cbc10-ar-6cbc10a.pkl. "
BLCA,,,excluded,NR,"I am managing a male patient with bladder urothelial carcinoma. His mRNA TPM expression was assessed from a lymph node biopsy to evaluate the tumor immune microenvironment, but his tumor mutational burden (TMB) is reported as not available. Given these findings, how likely is he to respond to treatment with atezolizumab?","I am managing a male patient with bladder urothelial carcinoma. His mRNA TPM expression was assessed from a lymph node biopsy to evaluate the tumor immune microenvironment, but his tumor mutational burden (TMB) is reported as not available. Given these findings, how likely is he to respond to treatment with atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/6d2ae0-ar-6d2ae0c.pkl. "
BLCA,,3.568627451,,NR,"A patient with bladder urothelial carcinoma has had an mRNA analysis from a bladder biopsy assessing the tumor immune microenvironment, and their tumor mutational burden is reported as ""nan."" Given these findings, how likely is the patient to respond to Atezolizumab therapy?","A patient with bladder urothelial carcinoma has had an mRNA analysis from a bladder biopsy assessing the tumor immune microenvironment, and their tumor mutational burden is reported as ""nan."" Given these findings, how likely is the patient to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/6dd7ad-ar-6dd7ad1.pkl. "
BLCA,8.0,2.078431373,,R,"For a female patient with bladder urothelial carcinoma who has undergone a nano-biopsy assessing mRNA TPM expression and has a tumor mutational burden of 8.0, how likely is it that she will respond to Atezolizumab therapy?","For a female patient with bladder urothelial carcinoma who has undergone a nano-biopsy assessing mRNA TPM expression and has a tumor mutational burden of 8.0, how likely is it that she will respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/6f2a10-ar-6f2a102.pkl. "
BLCA,6.0,1.039215686,excluded,R,"For a male patient with bladder urothelial carcinoma who has a tumor mutational burden of 6.0 and mRNA TPM expression data from a kidney biopsy assessing the tumor immune microenvironment, is Atezolizumab likely to be effective?","For a male patient with bladder urothelial carcinoma who has a tumor mutational burden of 6.0 and mRNA TPM expression data from a kidney biopsy assessing the tumor immune microenvironment, is Atezolizumab likely to be effective?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/6ff654-ar-6ff654a.pkl. "
BLCA,17.0,2.176470588,,NR,"We have a male patient with bladder urothelial carcinoma, a tumor mutational burden of 17.0, and mRNA TPM expression measured from a bladder biopsy evaluating the tumor immune microenvironment. Based on these factors, is he likely to benefit from Atezolizumab therapy?","We have a male patient with bladder urothelial carcinoma, a tumor mutational burden of 17.0, and mRNA TPM expression measured from a bladder biopsy evaluating the tumor immune microenvironment. Based on these factors, is he likely to benefit from Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/7114d9-ar-7114d99.pkl. "
BLCA,6.0,1.568627451,,NR,"I have a male patient diagnosed with bladder urothelial carcinoma whose kidney biopsy mRNA TPM expression was used to assess the tumor immune microenvironment, and his tumor mutational burden is 6.0. Based on these factors, how likely is he to respond to Atezolizumab?","I have a male patient diagnosed with bladder urothelial carcinoma whose kidney biopsy mRNA TPM expression was used to assess the tumor immune microenvironment, and his tumor mutational burden is 6.0. Based on these factors, how likely is he to respond to Atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/716f54-ar-716f54e.pkl. "
BLCA,1.0,0.333333333,,R,"In a male patient with bladder urothelial carcinoma, a lymph node biopsy was performed to assess the tumor immune microenvironment via mRNA TPM expression analysis, and his tumor mutational burden is 1.0. How likely is he to respond to atezolizumab therapy based on these factors?","In a male patient with bladder urothelial carcinoma, a lymph node biopsy was performed to assess the tumor immune microenvironment via mRNA TPM expression analysis, and his tumor mutational burden is 1.0. How likely is he to respond to atezolizumab therapy based on these factors?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/727c0e-ar-727c0e9.pkl. "
BLCA,,,excluded,R,"I have a patient with bladder urothelial carcinoma whose mRNA TPM expression was measured via a kidney biopsy to evaluate the tumor immune microenvironment, and the reported tumor mutational burden is ""nan."" Based on these factors, what is the expected likelihood of response to atezolizumab therapy?","I have a patient with bladder urothelial carcinoma whose mRNA TPM expression was measured via a kidney biopsy to evaluate the tumor immune microenvironment, and the reported tumor mutational burden is ""nan."" Based on these factors, what is the expected likelihood of response to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/73663e-ar-73663ee.pkl. "
BLCA,7.0,0.274509804,excluded,NR,"I have a female patient with bladder urothelial carcinoma who underwent a kidney biopsy for mRNA expression profiling (TPM) to assess the tumor's immune microenvironment. With a tumor mutational burden of 7.0 mutations per megabase, how likely is it that she will respond to Atezolizumab therapy?","I have a female patient with bladder urothelial carcinoma who underwent a kidney biopsy for mRNA expression profiling (TPM) to assess the tumor's immune microenvironment. With a tumor mutational burden of 7.0 mutations per megabase, how likely is it that she will respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/75142f-ar-75142fc.pkl. "
BLCA,21.0,2.392156863,inflamed,NR,"In a female patient with bladder urothelial carcinoma who has a tumor mutational burden of 21.0 and mRNA TPM expression measurements from a bladder biopsy assessing the tumor immune microenvironment, how likely is she to respond to atezolizumab therapy?","In a female patient with bladder urothelial carcinoma who has a tumor mutational burden of 21.0 and mRNA TPM expression measurements from a bladder biopsy assessing the tumor immune microenvironment, how likely is she to respond to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/7538ad-ar-7538ad9.pkl. "
BLCA,7.0,,excluded,NR,"My male patient has bladder urothelial carcinoma, and we evaluated his tumor immune microenvironment using mRNA TPM expression from a ureter biopsy. His tumor mutational burden is 7.0 mutations per megabase. Based on these findings, would he likely benefit from Atezolizumab therapy?","My male patient has bladder urothelial carcinoma, and we evaluated his tumor immune microenvironment using mRNA TPM expression from a ureter biopsy. His tumor mutational burden is 7.0 mutations per megabase. Based on these findings, would he likely benefit from Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/753d4b-ar-753d4bb.pkl. "
BLCA,6.0,0.333333333,inflamed,NR,"I am evaluating a male patient with bladder urothelial carcinoma whose mRNA TPM expression was assessed from a lung biopsy to characterize the tumor immune microenvironment. With a tumor mutational burden of 6.0, what is the likelihood that he will respond favorably to Atezolizumab therapy?","I am evaluating a male patient with bladder urothelial carcinoma whose mRNA TPM expression was assessed from a lung biopsy to characterize the tumor immune microenvironment. With a tumor mutational burden of 6.0, what is the likelihood that he will respond favorably to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/75f12d-ar-75f12d1.pkl. "
BLCA,6.0,0.215686275,inflamed,NR,"In a male patient with bladder urothelial carcinoma, mRNA TPM expression from a kidney biopsy has been used to assess the tumor immune microenvironment, and the tumor exhibits a mutational burden of 6.0. Given these molecular characteristics, is this patient likely to benefit from atezolizumab therapy?","In a male patient with bladder urothelial carcinoma, mRNA TPM expression from a kidney biopsy has been used to assess the tumor immune microenvironment, and the tumor exhibits a mutational burden of 6.0. Given these molecular characteristics, is this patient likely to benefit from atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/76a431-ar-76a431b.pkl. "
BLCA,,0.215686275,inflamed,R,"In a male patient with bladder urothelial carcinoma who underwent a bladder biopsy for mRNA TPM expression profiling of the tumor immune microenvironment—with a tumor mutational burden reported as ""nan""—what is the expected response to Atezolizumab therapy?","In a male patient with bladder urothelial carcinoma who underwent a bladder biopsy for mRNA TPM expression profiling of the tumor immune microenvironment—with a tumor mutational burden reported as ""nan""—what is the expected response to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/771445-ar-771445e.pkl. "
BLCA,3.0,0.745098039,inflamed,NR,"For a patient with bladder urothelial carcinoma who has undergone mRNA TPM expression analysis of the tumor immune microenvironment from a bladder biopsy and has a tumor mutational burden of 3.0, what is the likelihood of a favorable response to atezolizumab therapy?","For a patient with bladder urothelial carcinoma who has undergone mRNA TPM expression analysis of the tumor immune microenvironment from a bladder biopsy and has a tumor mutational burden of 3.0, what is the likelihood of a favorable response to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/7829a3-ar-7829a34.pkl. "
BLCA,5.0,0.941176471,,NR,"For a patient with bladder urothelial carcinoma who has undergone a bladder biopsy assessing mRNA TPM expression of the tumor immune microenvironment and has a tumor mutational burden of 5.0, would treatment with atezolizumab be expected to yield a favorable clinical response?","For a patient with bladder urothelial carcinoma who has undergone a bladder biopsy assessing mRNA TPM expression of the tumor immune microenvironment and has a tumor mutational burden of 5.0, would treatment with atezolizumab be expected to yield a favorable clinical response?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/789319-ar-7893196.pkl. "
BLCA,,1.039215686,excluded,NR,"A patient with bladder urothelial carcinoma has had mRNA TPM expression measured from a bladder biopsy to assess the tumor immune microenvironment, and the tumor mutational burden is reported as ""nan."" Given these details, can we expect this patient to respond to Atezolizumab therapy?","A patient with bladder urothelial carcinoma has had mRNA TPM expression measured from a bladder biopsy to assess the tumor immune microenvironment, and the tumor mutational burden is reported as ""nan."" Given these details, can we expect this patient to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/7aa01f-ar-7aa01fc.pkl. "
BLCA,12.0,,,R,"I have a female patient diagnosed with bladder urothelial carcinoma. Her tumor's mRNA TPM expression, obtained from a ureter biopsy, was analyzed to characterize the immune microenvironment, and her tumor mutational burden is 12.0. Based on these molecular features, what is the likelihood that she will respond to treatment with atezolizumab?","I have a female patient diagnosed with bladder urothelial carcinoma. Her tumor's mRNA TPM expression, obtained from a ureter biopsy, was analyzed to characterize the immune microenvironment, and her tumor mutational burden is 12.0. Based on these molecular features, what is the likelihood that she will respond to treatment with atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/7b4000-ar-7b40007.pkl. "
BLCA,,0.725490196,,NR,"We have a male patient with bladder urothelial carcinoma (BLCA) who underwent a ureter biopsy for mRNA TPM expression analysis to assess the tumor immune microenvironment. The tumor mutational burden (TMB) data is not available (NaN). Considering the potential use of Atezolizumab, what factors should we evaluate to predict the likelihood of a favorable response in this patient?","We have a male patient with bladder urothelial carcinoma (BLCA) who underwent a ureter biopsy for mRNA TPM expression analysis to assess the tumor immune microenvironment. The tumor mutational burden (TMB) data is not available (NaN). Considering the potential use of Atezolizumab, what factors should we evaluate to predict the likelihood of a favorable response in this patient?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/7bff23-ar-7bff231.pkl. "
BLCA,5.0,0.529411765,,NR,"I have a female patient diagnosed with bladder urothelial carcinoma. Her bladder biopsy provided mRNA TPM expression data to evaluate the tumor immune microenvironment, and her tumor mutational burden (TMB) is 5.0. Based on these findings, would treatment with Atezolizumab be expected to be effective?","I have a female patient diagnosed with bladder urothelial carcinoma. Her bladder biopsy provided mRNA TPM expression data to evaluate the tumor immune microenvironment, and her tumor mutational burden (TMB) is 5.0. Based on these findings, would treatment with Atezolizumab be expected to be effective?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/7c67b0-ar-7c67b05.pkl. "
BLCA,4.0,0.156862745,inflamed,NR,"In a patient with bladder urothelial carcinoma whose tumor immune microenvironment was evaluated through mRNA TPM expression from a lymph node biopsy and who has a tumor mutational burden of 4.0, would treatment with Atezolizumab be expected to yield a clinical response?","In a patient with bladder urothelial carcinoma whose tumor immune microenvironment was evaluated through mRNA TPM expression from a lymph node biopsy and who has a tumor mutational burden of 4.0, would treatment with Atezolizumab be expected to yield a clinical response?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/7d2dfb-ar-7d2dfba.pkl. "
BLCA,8.0,2.098039216,excluded,R,"For a male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden of 8.0 and mRNA TPM expression data from a bladder biopsy evaluating the tumor immune microenvironment, is he likely to respond favorably to Atezolizumab therapy?","For a male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden of 8.0 and mRNA TPM expression data from a bladder biopsy evaluating the tumor immune microenvironment, is he likely to respond favorably to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/7d7c54-ar-7d7c546.pkl. "
BLCA,,,excluded,NR,"I have a patient with bladder urothelial carcinoma (BLCA) whose tumor immune microenvironment was evaluated using mRNA TPM expression from a bladder biopsy; however, the tumor mutational burden (TMB) is reported as nan. Given these findings, what is the likelihood that the patient will respond to treatment with atezolizumab?","I have a patient with bladder urothelial carcinoma (BLCA) whose tumor immune microenvironment was evaluated using mRNA TPM expression from a bladder biopsy; however, the tumor mutational burden (TMB) is reported as nan. Given these findings, what is the likelihood that the patient will respond to treatment with atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/7f0d9c-ar-7f0d9cc.pkl. "
BLCA,1.0,,excluded,NR,"In a patient with bladder urothelial carcinoma, mRNA TPM expression obtained from a bladder biopsy was used to evaluate the tumor immune microenvironment, and the tumor mutational burden is 1.0. Given these findings, how likely is the patient to respond to Atezolizumab therapy?","In a patient with bladder urothelial carcinoma, mRNA TPM expression obtained from a bladder biopsy was used to evaluate the tumor immune microenvironment, and the tumor mutational burden is 1.0. Given these findings, how likely is the patient to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/7fb698-ar-7fb6987.pkl. "
BLCA,11.0,0.764705882,excluded,NR,"A male patient with bladder urothelial carcinoma had mRNA TPM expression analyzed from a kidney biopsy to assess the tumor immune microenvironment, and his tumor mutational burden is 11.0. Based on these parameters, how likely is he to respond to Atezolizumab treatment?","A male patient with bladder urothelial carcinoma had mRNA TPM expression analyzed from a kidney biopsy to assess the tumor immune microenvironment, and his tumor mutational burden is 11.0. Based on these parameters, how likely is he to respond to Atezolizumab treatment?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/7fb7a1-ar-7fb7a13.pkl. "
BLCA,8.0,0.215686275,inflamed,NR,"For a male patient with bladder urothelial carcinoma whose tumor immune microenvironment has been assessed via mRNA TPM expression from a kidney biopsy and who has a tumor mutational burden of 8.0, how likely is it that he will respond to atezolizumab therapy?","For a male patient with bladder urothelial carcinoma whose tumor immune microenvironment has been assessed via mRNA TPM expression from a kidney biopsy and who has a tumor mutational burden of 8.0, how likely is it that he will respond to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/80c618-ar-80c6183.pkl. "
BLCA,7.0,1.078431373,,NR,"I have a female patient with bladder urothelial carcinoma for whom we measured mRNA TPM expression from a bladder biopsy to assess the tumor immune microenvironment, and her tumor mutational burden is 7.0. Given these factors, what is her likelihood of responding to atezolizumab therapy?","I have a female patient with bladder urothelial carcinoma for whom we measured mRNA TPM expression from a bladder biopsy to assess the tumor immune microenvironment, and her tumor mutational burden is 7.0. Given these factors, what is her likelihood of responding to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/81b715-ar-81b7152.pkl. "
BLCA,,1.098039216,desert,NR,"I have a male patient with bladder urothelial carcinoma. mRNA TPM expression analysis from a separate biopsy was used to evaluate the tumor immune microenvironment, but the reported tumor mutational burden (TMB) is ""nan."" Considering these findings, can we anticipate a favorable response to Atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma. mRNA TPM expression analysis from a separate biopsy was used to evaluate the tumor immune microenvironment, but the reported tumor mutational burden (TMB) is ""nan."" Considering these findings, can we anticipate a favorable response to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/822b22-ar-822b226.pkl. "
BLCA,5.0,1.725490196,desert,R,"In a male patient with bladder urothelial carcinoma, mRNA TPM expression from a bladder biopsy was used to assess the tumor immune microenvironment, and the tumor mutational burden is 5.0. Considering these findings, what is the likelihood of a favorable response to Atezolizumab therapy?","In a male patient with bladder urothelial carcinoma, mRNA TPM expression from a bladder biopsy was used to assess the tumor immune microenvironment, and the tumor mutational burden is 5.0. Considering these findings, what is the likelihood of a favorable response to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/8533e5-ar-8533e5e.pkl. "
BLCA,8.0,0.274509804,excluded,NR,"For a patient with bladder urothelial carcinoma whose lung biopsy revealed mRNA TPM expression indicative of the tumor immune microenvironment and a tumor mutational burden of 8.0, how likely is it that treatment with Atezolizumab will be effective?","For a patient with bladder urothelial carcinoma whose lung biopsy revealed mRNA TPM expression indicative of the tumor immune microenvironment and a tumor mutational burden of 8.0, how likely is it that treatment with Atezolizumab will be effective?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/85f0a3-ar-85f0a3a.pkl. "
BLCA,14.0,0.31372549,excluded,NR,"For a female patient with bladder urothelial carcinoma, mRNA TPM expression profiling from a bladder biopsy was used to assess the tumor immune microenvironment, and the tumor mutational burden is 14.0. Based on these findings, what is the likelihood of a favorable response to atezolizumab therapy?","For a female patient with bladder urothelial carcinoma, mRNA TPM expression profiling from a bladder biopsy was used to assess the tumor immune microenvironment, and the tumor mutational burden is 14.0. Based on these findings, what is the likelihood of a favorable response to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/87a8e1-ar-87a8e18.pkl. "
BLCA,13.0,6.0,inflamed,R,"In a patient with bladder urothelial carcinoma (BLCA) whose tumor immune microenvironment was assessed via mRNA TPM expression from a bladder biopsy, and with a tumor mutational burden (TMB) of 13.0, how likely is the patient to respond to Atezolizumab therapy?","In a patient with bladder urothelial carcinoma (BLCA) whose tumor immune microenvironment was assessed via mRNA TPM expression from a bladder biopsy, and with a tumor mutational burden (TMB) of 13.0, how likely is the patient to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/8884fe-ar-8884fe4.pkl. "
BLCA,14.0,0.843137255,desert,R,"I have a male patient with bladder urothelial carcinoma who has a tumor mutational burden of 14.0 and mRNA TPM expression data from a bladder biopsy assessing the tumor immune microenvironment. Considering these molecular findings, would you anticipate a favorable response to atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma who has a tumor mutational burden of 14.0 and mRNA TPM expression data from a bladder biopsy assessing the tumor immune microenvironment. Considering these molecular findings, would you anticipate a favorable response to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/8a1b0e-ar-8a1b0e0.pkl. "
BLCA,7.0,1.0,excluded,NR,"In a male patient with bladder urothelial carcinoma, mRNA TPM expression analysis from a kidney biopsy was used to evaluate the tumor immune microenvironment, and the tumor mutational burden is 7.0. Given these findings, what is the likelihood that the patient will respond to Atezolizumab therapy?","In a male patient with bladder urothelial carcinoma, mRNA TPM expression analysis from a kidney biopsy was used to evaluate the tumor immune microenvironment, and the tumor mutational burden is 7.0. Given these findings, what is the likelihood that the patient will respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/8b4b8b-ar-8b4b8b0.pkl. "
BLCA,6.0,,excluded,NR,"We have a male patient with bladder urothelial carcinoma whose tumor mRNA expression was measured via TPM from a bladder biopsy to evaluate the immune microenvironment. With a tumor mutational burden of 6.0, how likely is he to respond to treatment with atezolizumab?","We have a male patient with bladder urothelial carcinoma whose tumor mRNA expression was measured via TPM from a bladder biopsy to evaluate the immune microenvironment. With a tumor mutational burden of 6.0, how likely is he to respond to treatment with atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/8e4698-ar-8e46983.pkl. "
BLCA,6.0,0.509803922,desert,NR,"In a patient with bladder urothelial carcinoma whose mRNA TPM expression from a kidney biopsy was used to assess the tumor immune microenvironment and with a tumor mutational burden of 6.0, would you expect a favorable response to atezolizumab treatment?","In a patient with bladder urothelial carcinoma whose mRNA TPM expression from a kidney biopsy was used to assess the tumor immune microenvironment and with a tumor mutational burden of 6.0, would you expect a favorable response to atezolizumab treatment?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/8e8ef2-ar-8e8ef23.pkl. "
BLCA,5.0,,desert,NR,"I have a male patient with bladder urothelial carcinoma who underwent an mRNA TPM expression analysis from a bladder biopsy to evaluate the tumor immune microenvironment. The tumor mutational burden is 5.0. Given these details, would this patient be a likely candidate to respond to Atezolizumab?","I have a male patient with bladder urothelial carcinoma who underwent an mRNA TPM expression analysis from a bladder biopsy to evaluate the tumor immune microenvironment. The tumor mutational burden is 5.0. Given these details, would this patient be a likely candidate to respond to Atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/8f2275-ar-8f2275c.pkl. "
BLCA,49.0,2.705882353,inflamed,R,"For a male patient with bladder urothelial carcinoma who has a tumor mutational burden of 49.0 and mRNA TPM expression data from a bladder biopsy used to assess the tumor immune microenvironment, is treatment with atezolizumab likely to be effective?","For a male patient with bladder urothelial carcinoma who has a tumor mutational burden of 49.0 and mRNA TPM expression data from a bladder biopsy used to assess the tumor immune microenvironment, is treatment with atezolizumab likely to be effective?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/91c47b-ar-91c47b0.pkl. "
BLCA,12.0,2.235294118,inflamed,NR,"For a male patient with bladder urothelial carcinoma who has undergone a bladder biopsy showing mRNA TPM expression to evaluate the tumor immune microenvironment and a tumor mutational burden of 12.0, would you expect a favorable response to Atezolizumab therapy?","For a male patient with bladder urothelial carcinoma who has undergone a bladder biopsy showing mRNA TPM expression to evaluate the tumor immune microenvironment and a tumor mutational burden of 12.0, would you expect a favorable response to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/9306c5-ar-9306c5c.pkl. "
BLCA,,,,NR,"I have a male patient with bladder urothelial carcinoma. We assessed the tumor immune microenvironment via mRNA TPM expression from a bladder biopsy, but his tumor mutational burden data is unavailable. Given these factors, could you provide insight into whether he is likely to respond to atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma. We assessed the tumor immune microenvironment via mRNA TPM expression from a bladder biopsy, but his tumor mutational burden data is unavailable. Given these factors, could you provide insight into whether he is likely to respond to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/9410b8-ar-9410b86.pkl. "
BLCA,5.0,0.117647059,desert,NR,"In a male patient with bladder urothelial carcinoma (BLCA) who has undergone mRNA TPM expression analysis from a bladder biopsy to assess the tumor immune microenvironment and has a tumor mutational burden (TMB) of 5.0, what is the likelihood that he will respond to Atezolizumab therapy?","In a male patient with bladder urothelial carcinoma (BLCA) who has undergone mRNA TPM expression analysis from a bladder biopsy to assess the tumor immune microenvironment and has a tumor mutational burden (TMB) of 5.0, what is the likelihood that he will respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/943df5-ar-943df5c.pkl. "
BLCA,11.0,0.215686275,excluded,NR,"A patient with bladder urothelial carcinoma (BLCA) underwent mRNA TPM expression analysis from a kidney biopsy to evaluate the tumor immune microenvironment and has a tumor mutational burden (TMB) of 11.0. Based on these findings, what is the likelihood of a positive therapeutic response to Atezolizumab?","A patient with bladder urothelial carcinoma (BLCA) underwent mRNA TPM expression analysis from a kidney biopsy to evaluate the tumor immune microenvironment and has a tumor mutational burden (TMB) of 11.0. Based on these findings, what is the likelihood of a positive therapeutic response to Atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/94859b-ar-94859b4.pkl. "
BLCA,,0.431372549,desert,NR,"In a male patient with bladder urothelial carcinoma, mRNA TPM expression from a bladder biopsy has been evaluated to assess the tumor immune microenvironment, but the tumor mutational burden data is not available. Based on these parameters, how likely is it that the patient will respond to atezolizumab therapy?","In a male patient with bladder urothelial carcinoma, mRNA TPM expression from a bladder biopsy has been evaluated to assess the tumor immune microenvironment, but the tumor mutational burden data is not available. Based on these parameters, how likely is it that the patient will respond to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/9539a4-ar-9539a4f.pkl. "
BLCA,,0.196078431,excluded,NR,"I have a male patient with bladder urothelial carcinoma who underwent a ureter biopsy to assess the tumor immune microenvironment via mRNA TPM expression analysis. The tumor mutational burden (TMB) data is not available. Considering treatment with atezolizumab, what is the likelihood of a favorable response based on this information?","I have a male patient with bladder urothelial carcinoma who underwent a ureter biopsy to assess the tumor immune microenvironment via mRNA TPM expression analysis. The tumor mutational burden (TMB) data is not available. Considering treatment with atezolizumab, what is the likelihood of a favorable response based on this information?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/957378-ar-957378b.pkl. "
BLCA,17.0,1.725490196,excluded,NR,"In a male patient with bladder urothelial carcinoma, a bladder biopsy revealed specific mRNA TPM expression levels reflecting the tumor immune microenvironment and a tumor mutational burden of 17. Considering these findings, would you anticipate a favorable response to Atezolizumab therapy?","In a male patient with bladder urothelial carcinoma, a bladder biopsy revealed specific mRNA TPM expression levels reflecting the tumor immune microenvironment and a tumor mutational burden of 17. Considering these findings, would you anticipate a favorable response to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/961d04-ar-961d04c.pkl. "
BLCA,22.0,4.431372549,desert,NR,"I'm managing a male patient with bladder urothelial carcinoma who underwent a bladder biopsy for mRNA TPM expression profiling to assess the tumor immune microenvironment. With a tumor mutational burden of 22.0, what is your assessment of his likelihood to respond to atezolizumab therapy?","I'm managing a male patient with bladder urothelial carcinoma who underwent a bladder biopsy for mRNA TPM expression profiling to assess the tumor immune microenvironment. With a tumor mutational burden of 22.0, what is your assessment of his likelihood to respond to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/972530-ar-9725303.pkl. "
BLCA,,1.921568627,excluded,NR,In a male patient with bladder urothelial carcinoma who underwent a bladder biopsy for mRNA TPM expression profiling of the tumor immune microenvironment—with a reported tumor mutational burden of “nan”—how likely is it that treatment with Atezolizumab will be effective?,In a male patient with bladder urothelial carcinoma who underwent a bladder biopsy for mRNA TPM expression profiling of the tumor immune microenvironment—with a reported tumor mutational burden of “nan”—how likely is it that treatment with Atezolizumab will be effective?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/978a58-ar-978a587.pkl. 
BLCA,18.0,2.862745098,excluded,R,"In a male patient with bladder urothelial carcinoma, mRNA TPM expression was analyzed from a kidney biopsy to evaluate the tumor immune microenvironment, and the tumor mutational burden is 18 mutations per megabase. Considering these factors, what is the likelihood that the patient will respond to Atezolizumab therapy?","In a male patient with bladder urothelial carcinoma, mRNA TPM expression was analyzed from a kidney biopsy to evaluate the tumor immune microenvironment, and the tumor mutational burden is 18 mutations per megabase. Considering these factors, what is the likelihood that the patient will respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/97a00e-ar-97a00e0.pkl. "
BLCA,5.0,0.725490196,excluded,NR,"I have a male patient with bladder urothelial carcinoma whose tumor mRNA TPM expression was measured from a kidney biopsy to evaluate the tumor immune microenvironment, and his tumor mutational burden is 5.0. Based on these factors, how likely is it that he will respond to Atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma whose tumor mRNA TPM expression was measured from a kidney biopsy to evaluate the tumor immune microenvironment, and his tumor mutational burden is 5.0. Based on these factors, how likely is it that he will respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/99a46b-ar-99a46b9.pkl. "
BLCA,4.0,0.862745098,inflamed,NR,"In a male patient with bladder urothelial carcinoma (BLCA), whose bladder biopsy showed mRNA TPM expression indicative of the tumor immune microenvironment and a tumor mutational burden (TMB) of 4.0, would treatment with atezolizumab be expected to result in a favorable response?","In a male patient with bladder urothelial carcinoma (BLCA), whose bladder biopsy showed mRNA TPM expression indicative of the tumor immune microenvironment and a tumor mutational burden (TMB) of 4.0, would treatment with atezolizumab be expected to result in a favorable response?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/9a2cf3-ar-9a2cf3c.pkl. "
BLCA,5.0,0.647058824,excluded,NR,"In a male patient with bladder urothelial carcinoma, kidney biopsy analysis revealed mRNA TPM expression levels to assess the tumor immune microenvironment, and the tumor mutational burden is 5.0. Based on these findings, how likely is he to respond to Atezolizumab therapy?","In a male patient with bladder urothelial carcinoma, kidney biopsy analysis revealed mRNA TPM expression levels to assess the tumor immune microenvironment, and the tumor mutational burden is 5.0. Based on these findings, how likely is he to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/9aa6a0-ar-9aa6a09.pkl. "
BLCA,12.0,0.588235294,inflamed,NR,"I have a male patient with bladder urothelial carcinoma whose tumor immune microenvironment has been characterized by mRNA TPM expression from a kidney biopsy. With a tumor mutational burden of 12.0, what is the likelihood that he will respond to treatment with atezolizumab?","I have a male patient with bladder urothelial carcinoma whose tumor immune microenvironment has been characterized by mRNA TPM expression from a kidney biopsy. With a tumor mutational burden of 12.0, what is the likelihood that he will respond to treatment with atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/9cafb9-ar-9cafb90.pkl. "
BLCA,,,,NR,"I have a male patient with bladder urothelial carcinoma (BLCA) who underwent a liver biopsy to assess the tumor immune microenvironment via mRNA TPM expression analysis. However, the tumor mutational burden (TMB) data is not available. Given these factors, how likely is the patient to respond to atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma (BLCA) who underwent a liver biopsy to assess the tumor immune microenvironment via mRNA TPM expression analysis. However, the tumor mutational burden (TMB) data is not available. Given these factors, how likely is the patient to respond to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/9d2494-ar-9d24941.pkl. "
BLCA,,,desert,NR,"I have a female patient with bladder urothelial carcinoma (BLCA) who underwent a kidney biopsy for mRNA TPM expression analysis to evaluate the tumor immune microenvironment. The reported tumor mutational burden (TMB) is ""nan."" Considering these findings, is she likely to respond to treatment with Atezolizumab?","I have a female patient with bladder urothelial carcinoma (BLCA) who underwent a kidney biopsy for mRNA TPM expression analysis to evaluate the tumor immune microenvironment. The reported tumor mutational burden (TMB) is ""nan."" Considering these findings, is she likely to respond to treatment with Atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/9dacca-ar-9daccaf.pkl. "
BLCA,10.0,,inflamed,NR,"I have a male patient with bladder urothelial carcinoma whose tumor mRNA TPM expression was measured to assess the immune microenvironment, and the tumor mutational burden is 10.0 mutations per megabase. Considering these factors, what is the likelihood that he would respond to atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma whose tumor mRNA TPM expression was measured to assess the immune microenvironment, and the tumor mutational burden is 10.0 mutations per megabase. Considering these factors, what is the likelihood that he would respond to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/9e11ec-ar-9e11ec6.pkl. "
BLCA,6.0,0.431372549,desert,NR,"We have a female patient with bladder urothelial carcinoma whose biopsy revealed specific mRNA TPM expression profiles to evaluate the tumor immune microenvironment and a tumor mutational burden of 6.0. Based on these findings, would you expect the patient to respond favorably to atezolizumab therapy?","We have a female patient with bladder urothelial carcinoma whose biopsy revealed specific mRNA TPM expression profiles to evaluate the tumor immune microenvironment and a tumor mutational burden of 6.0. Based on these findings, would you expect the patient to respond favorably to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/9fb814-ar-9fb814c.pkl. "
BLCA,,3.333333333,desert,NR,"I have a female patient with bladder urothelial carcinoma. A bladder biopsy was performed to evaluate the tumor immune microenvironment using mRNA TPM expression data, though the tumor mutational burden is not available. Given these parameters, what is the likelihood that she will respond to atezolizumab therapy?","I have a female patient with bladder urothelial carcinoma. A bladder biopsy was performed to evaluate the tumor immune microenvironment using mRNA TPM expression data, though the tumor mutational burden is not available. Given these parameters, what is the likelihood that she will respond to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/a1871f-ar-a1871f4.pkl. "
BLCA,15.0,0.921568627,inflamed,NR,"I have a female patient with bladder urothelial carcinoma whose tumor immune microenvironment was evaluated using mRNA TPM expression from a bladder biopsy. The patient has a tumor mutational burden of 15.0. Based on these findings, what is the likelihood that she will respond to Atezolizumab therapy?","I have a female patient with bladder urothelial carcinoma whose tumor immune microenvironment was evaluated using mRNA TPM expression from a bladder biopsy. The patient has a tumor mutational burden of 15.0. Based on these findings, what is the likelihood that she will respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/a1e62d-ar-a1e62d3.pkl. "
BLCA,8.0,1.411764706,excluded,NR,"I have a male patient with bladder urothelial carcinoma whose lymph node biopsy revealed mRNA TPM expression levels for immune microenvironment assessment, with a tumor mutational burden of 8.0. Based on these parameters, how likely is it that the patient will benefit from Atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma whose lymph node biopsy revealed mRNA TPM expression levels for immune microenvironment assessment, with a tumor mutational burden of 8.0. Based on these parameters, how likely is it that the patient will benefit from Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/a32177-ar-a321770.pkl. "
BLCA,6.0,0.68627451,,NR,"In a male patient with bladder urothelial carcinoma, mRNA TPM expression analysis from a bladder biopsy was performed to assess the tumor immune microenvironment. With a tumor mutational burden of 6.0, how likely is it that the patient will respond to Atezolizumab treatment?","In a male patient with bladder urothelial carcinoma, mRNA TPM expression analysis from a bladder biopsy was performed to assess the tumor immune microenvironment. With a tumor mutational burden of 6.0, how likely is it that the patient will respond to Atezolizumab treatment?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/a424c7-ar-a424c75.pkl. "
BLCA,19.0,0.882352941,,R,"For a patient with bladder urothelial carcinoma (BLCA) who has undergone a bladder biopsy with mRNA TPM expression analysis and has a tumor mutational burden (TMB) of 19.0, what is the likelihood of a favorable response to Atezolizumab therapy?","For a patient with bladder urothelial carcinoma (BLCA) who has undergone a bladder biopsy with mRNA TPM expression analysis and has a tumor mutational burden (TMB) of 19.0, what is the likelihood of a favorable response to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/a535fc-ar-a535fcd.pkl. "
BLCA,12.0,0.725490196,,NR,"For a male patient with bladder urothelial carcinoma who has a tumor mutational burden of 12.0 and mRNA TPM expression data from an alternate biopsy to assess the tumor immune microenvironment, do these parameters suggest that treatment with atezolizumab is likely to be effective?","For a male patient with bladder urothelial carcinoma who has a tumor mutational burden of 12.0 and mRNA TPM expression data from an alternate biopsy to assess the tumor immune microenvironment, do these parameters suggest that treatment with atezolizumab is likely to be effective?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/a90d73-ar-a90d73f.pkl. "
BLCA,,1.529411765,excluded,NR,"We have a male patient with bladder urothelial carcinoma who underwent a kidney biopsy for mRNA TPM expression analysis to assess the tumor immune microenvironment. The tumor mutational burden data is not available. Considering the potential use of Atezolizumab, how likely is it that this patient will respond to the therapy based on the available molecular profiling?","We have a male patient with bladder urothelial carcinoma who underwent a kidney biopsy for mRNA TPM expression analysis to assess the tumor immune microenvironment. The tumor mutational burden data is not available. Considering the potential use of Atezolizumab, how likely is it that this patient will respond to the therapy based on the available molecular profiling?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/a913c6-ar-a913c61.pkl. "
BLCA,3.0,0.352941176,,NR,"For a male patient with bladder urothelial carcinoma, whose tumor immune microenvironment has been evaluated using mRNA TPM expression analysis from a bladder biopsy and who has a tumor mutational burden of 3.0, would treatment with Atezolizumab be expected to yield a favorable response?","For a male patient with bladder urothelial carcinoma, whose tumor immune microenvironment has been evaluated using mRNA TPM expression analysis from a bladder biopsy and who has a tumor mutational burden of 3.0, would treatment with Atezolizumab be expected to yield a favorable response?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/a9ca85-ar-a9ca853.pkl. "
BLCA,18.0,2.0,,NR,For a patient with bladder urothelial carcinoma and a tumor mutational burden of 18.0—whose lymph node biopsy has been used to assess the tumor immune microenvironment via mRNA TPM expression—is treatment with Atezolizumab likely to be effective?,For a patient with bladder urothelial carcinoma and a tumor mutational burden of 18.0—whose lymph node biopsy has been used to assess the tumor immune microenvironment via mRNA TPM expression—is treatment with Atezolizumab likely to be effective?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/aabf4a-ar-aabf4af.pkl. 
BLCA,15.0,1.725490196,excluded,R,"For a male patient with bladder urothelial carcinoma, mRNA TPM expression profiling from a kidney biopsy was performed to evaluate the tumor immune microenvironment, and the tumor mutational burden is 15. Given these findings, would you anticipate a favorable response to atezolizumab therapy?","For a male patient with bladder urothelial carcinoma, mRNA TPM expression profiling from a kidney biopsy was performed to evaluate the tumor immune microenvironment, and the tumor mutational burden is 15. Given these findings, would you anticipate a favorable response to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/aaf505-ar-aaf505c.pkl. "
BLCA,,0.039215686,inflamed,NR,"For a male patient with bladder urothelial carcinoma who underwent lymph node biopsy for mRNA TPM expression analysis of the tumor immune microenvironment, with unavailable tumor mutational burden data, would you expect a favorable response to Atezolizumab therapy?","For a male patient with bladder urothelial carcinoma who underwent lymph node biopsy for mRNA TPM expression analysis of the tumor immune microenvironment, with unavailable tumor mutational burden data, would you expect a favorable response to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/ab8052-ar-ab8052a.pkl. "
BLCA,,,excluded,NR,"We have a patient with bladder urothelial carcinoma whose mRNA TPM expression was quantified from a bladder biopsy to evaluate the tumor immune microenvironment. However, the tumor mutational burden is reported as not available. Considering the potential use of atezolizumab, based on these factors, how likely is the patient to respond to this therapy?","We have a patient with bladder urothelial carcinoma whose mRNA TPM expression was quantified from a bladder biopsy to evaluate the tumor immune microenvironment. However, the tumor mutational burden is reported as not available. Considering the potential use of atezolizumab, based on these factors, how likely is the patient to respond to this therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/abc151-ar-abc151b.pkl. "
BLCA,6.0,0.745098039,,NR,"For a patient with bladder urothelial carcinoma who has a tumor mutational burden of 6.0 and mRNA TPM expression measured from a kidney biopsy to assess the tumor immune microenvironment, would treatment with atezolizumab likely produce a favorable response?","For a patient with bladder urothelial carcinoma who has a tumor mutational burden of 6.0 and mRNA TPM expression measured from a kidney biopsy to assess the tumor immune microenvironment, would treatment with atezolizumab likely produce a favorable response?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/ad83c9-ar-ad83c9c.pkl. "
BLCA,,,,NR,"I have a female patient with bladder urothelial carcinoma whose mRNA TPM expression was measured from a kidney biopsy to evaluate the tumor immune microenvironment. The tumor mutational burden is not available. Given these factors, what is the likelihood that she will respond to atezolizumab therapy?","I have a female patient with bladder urothelial carcinoma whose mRNA TPM expression was measured from a kidney biopsy to evaluate the tumor immune microenvironment. The tumor mutational burden is not available. Given these factors, what is the likelihood that she will respond to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/ae0262-ar-ae02629.pkl. "
BLCA,,,,NR,"For a male patient with bladder urothelial carcinoma whose tumor immune microenvironment was characterized via mRNA TPM expression from a ureter biopsy, and with an indeterminate (nan) tumor mutational burden, how likely is he to respond to Atezolizumab treatment?","For a male patient with bladder urothelial carcinoma whose tumor immune microenvironment was characterized via mRNA TPM expression from a ureter biopsy, and with an indeterminate (nan) tumor mutational burden, how likely is he to respond to Atezolizumab treatment?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/ae1690-ar-ae16904.pkl. "
BLCA,,,,NR,"For a female patient with bladder urothelial carcinoma who underwent mRNA TPM expression profiling from a bladder biopsy to assess the tumor immune microenvironment, and with a reported tumor mutational burden listed as “nan,” how would you evaluate her likelihood of responding to Atezolizumab therapy?","For a female patient with bladder urothelial carcinoma who underwent mRNA TPM expression profiling from a bladder biopsy to assess the tumor immune microenvironment, and with a reported tumor mutational burden listed as “nan,” how would you evaluate her likelihood of responding to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/ae4da2-ar-ae4da27.pkl. "
BLCA,4.0,,excluded,R,"In a male patient with bladder urothelial carcinoma, mRNA TPM expression profiling from a ureter biopsy was performed to evaluate the tumor immune microenvironment, and the tumor mutational burden was found to be 4.0. Based on these findings, how likely is the patient to respond to Atezolizumab therapy?","In a male patient with bladder urothelial carcinoma, mRNA TPM expression profiling from a ureter biopsy was performed to evaluate the tumor immune microenvironment, and the tumor mutational burden was found to be 4.0. Based on these findings, how likely is the patient to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/aec738-ar-aec7380.pkl. "
BLCA,14.0,2.196078431,inflamed,NR,"In a male patient with bladder urothelial carcinoma, where mRNA expression analysis from a bladder biopsy has been used to assess the tumor immune microenvironment and the tumor displays a mutational burden of 14.0 mutations per megabase, do these findings suggest that the patient is likely to respond well to Atezolizumab therapy?","In a male patient with bladder urothelial carcinoma, where mRNA expression analysis from a bladder biopsy has been used to assess the tumor immune microenvironment and the tumor displays a mutational burden of 14.0 mutations per megabase, do these findings suggest that the patient is likely to respond well to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/af42c1-ar-af42c15.pkl. "
BLCA,7.0,0.352941176,,NR,"In a male patient with bladder urothelial carcinoma and a tumor mutational burden of 7.0, for whom mRNA TPM levels were measured via lung biopsy to evaluate the tumor immune microenvironment, how likely is it that they will respond to Atezolizumab therapy?","In a male patient with bladder urothelial carcinoma and a tumor mutational burden of 7.0, for whom mRNA TPM levels were measured via lung biopsy to evaluate the tumor immune microenvironment, how likely is it that they will respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b0a83e-ar-b0a83e5.pkl. "
BLCA,3.0,0.843137255,inflamed,NR,"For a female patient with bladder urothelial carcinoma whose tumor immune profile was assessed via mRNA TPM expression from a lung biopsy and who has a tumor mutational burden of 3.0, would you expect a favorable response to atezolizumab?","For a female patient with bladder urothelial carcinoma whose tumor immune profile was assessed via mRNA TPM expression from a lung biopsy and who has a tumor mutational burden of 3.0, would you expect a favorable response to atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b0d11d-ar-b0d11db.pkl. "
BLCA,11.0,1.509803922,,R,"In a male patient with bladder urothelial carcinoma who has undergone a bladder biopsy for mRNA TPM expression analysis of the tumor immune microenvironment and presents with a tumor mutational burden of 11.0, would treatment with Atezolizumab be expected to yield a favorable response?","In a male patient with bladder urothelial carcinoma who has undergone a bladder biopsy for mRNA TPM expression analysis of the tumor immune microenvironment and presents with a tumor mutational burden of 11.0, would treatment with Atezolizumab be expected to yield a favorable response?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b15ac6-ar-b15ac6e.pkl. "
BLCA,4.0,,excluded,NR,"I have a female patient with bladder urothelial carcinoma. Her bladder biopsy indicates mRNA TPM expression for evaluation of the tumor immune microenvironment, and her tumor mutational burden is 4.0. Considering these findings, how likely is she to benefit from treatment with Atezolizumab?","I have a female patient with bladder urothelial carcinoma. Her bladder biopsy indicates mRNA TPM expression for evaluation of the tumor immune microenvironment, and her tumor mutational burden is 4.0. Considering these findings, how likely is she to benefit from treatment with Atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b15ad0-ar-b15ad09.pkl. "
BLCA,,,,NR,"I have a female patient with bladder urothelial carcinoma (BLCA). A bladder biopsy provided mRNA TPM expression data for assessing the tumor immune microenvironment, and the tumor mutational burden (TMB) is reported as ""nan."" Considering these factors, what is the likelihood of a positive response to Atezolizumab therapy?","I have a female patient with bladder urothelial carcinoma (BLCA). A bladder biopsy provided mRNA TPM expression data for assessing the tumor immune microenvironment, and the tumor mutational burden (TMB) is reported as ""nan."" Considering these factors, what is the likelihood of a positive response to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b2e4a0-ar-b2e4a08.pkl. "
BLCA,,0.862745098,desert,R,"A patient with bladder urothelial carcinoma has undergone a bladder biopsy with mRNA TPM expression evaluated to assess the tumor immune microenvironment, and their tumor mutational burden is reported as 'nan'. Based on this information, would you expect the patient to respond favorably to atezolizumab therapy?","A patient with bladder urothelial carcinoma has undergone a bladder biopsy with mRNA TPM expression evaluated to assess the tumor immune microenvironment, and their tumor mutational burden is reported as 'nan'. Based on this information, would you expect the patient to respond favorably to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b2f1d0-ar-b2f1d0e.pkl. "
BLCA,18.0,,desert,R,"In a male patient with bladder urothelial carcinoma, mRNA TPM expression from a separate biopsy was used to characterize the tumor immune microenvironment, and his tumor mutational burden is 18.0. Given these factors, what is the likelihood of a favorable therapeutic response to atezolizumab?","In a male patient with bladder urothelial carcinoma, mRNA TPM expression from a separate biopsy was used to characterize the tumor immune microenvironment, and his tumor mutational burden is 18.0. Given these factors, what is the likelihood of a favorable therapeutic response to atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b3c022-ar-b3c0229.pkl. "
BLCA,19.0,,excluded,R,"I have a male patient with bladder urothelial carcinoma whose tumor tissue analysis shows an mRNA TPM profile indicative of its immune microenvironment, and the tumor mutational burden is 19.0. Considering these factors, how likely is the patient to respond to treatment with atezolizumab?","I have a male patient with bladder urothelial carcinoma whose tumor tissue analysis shows an mRNA TPM profile indicative of its immune microenvironment, and the tumor mutational burden is 19.0. Considering these factors, how likely is the patient to respond to treatment with atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b419a8-ar-b419a8f.pkl. "
BLCA,35.0,,excluded,R,"I have a male patient with bladder urothelial carcinoma who has undergone a bladder biopsy, with mRNA TPM expression analyzed to assess the tumor immune microenvironment. The tumor mutational burden is 35.0. Based on these findings, would you anticipate that the patient would likely respond to atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma who has undergone a bladder biopsy, with mRNA TPM expression analyzed to assess the tumor immune microenvironment. The tumor mutational burden is 35.0. Based on these findings, would you anticipate that the patient would likely respond to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b470eb-ar-b470eb8.pkl. "
BLCA,5.0,,inflamed,NR,"In a male patient with bladder urothelial carcinoma, mRNA TPM expression was evaluated from a kidney biopsy to characterize the tumor immune microenvironment, and the tumor mutational burden is 5.0. Based on these findings, how likely is the patient to respond to atezolizumab therapy?","In a male patient with bladder urothelial carcinoma, mRNA TPM expression was evaluated from a kidney biopsy to characterize the tumor immune microenvironment, and the tumor mutational burden is 5.0. Based on these findings, how likely is the patient to respond to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b4c7a0-ar-b4c7a00.pkl. "
BLCA,5.0,0.333333333,desert,NR,"For a male patient with bladder urothelial carcinoma, whose tumor immune microenvironment was characterized using mRNA TPM expression from a bladder biopsy and who has a tumor mutational burden of 5.0, what is the likelihood of a favorable response to Atezolizumab therapy?","For a male patient with bladder urothelial carcinoma, whose tumor immune microenvironment was characterized using mRNA TPM expression from a bladder biopsy and who has a tumor mutational burden of 5.0, what is the likelihood of a favorable response to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b8070b-ar-b8070b7.pkl. "
BLCA,16.0,3.764705882,inflamed,NR,"In a male patient with bladder urothelial carcinoma who has a tumor mutational burden of 16.0 and mRNA TPM expression data from a bladder biopsy assessing the tumor immune microenvironment, how predictive are these findings of a favorable response to Atezolizumab therapy?","In a male patient with bladder urothelial carcinoma who has a tumor mutational burden of 16.0 and mRNA TPM expression data from a bladder biopsy assessing the tumor immune microenvironment, how predictive are these findings of a favorable response to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b8101c-ar-b8101c5.pkl. "
BLCA,8.0,0.882352941,excluded,NR,"In a patient with bladder urothelial carcinoma (BLCA) with a tumor mutational burden of 8.0 and mRNA TPM expression profiling from a bladder biopsy to evaluate the tumor immune microenvironment, would treatment with atezolizumab be expected to elicit a favorable response?","In a patient with bladder urothelial carcinoma (BLCA) with a tumor mutational burden of 8.0 and mRNA TPM expression profiling from a bladder biopsy to evaluate the tumor immune microenvironment, would treatment with atezolizumab be expected to elicit a favorable response?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b963dd-ar-b963dda.pkl. "
BLCA,5.0,0.901960784,inflamed,NR,"I have a male patient with bladder urothelial carcinoma whose mRNA expression, measured as TPM from a bladder biopsy, has been used to assess the tumor immune microenvironment. With a tumor mutational burden of 5.0, would you expect him to respond effectively to Atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma whose mRNA expression, measured as TPM from a bladder biopsy, has been used to assess the tumor immune microenvironment. With a tumor mutational burden of 5.0, would you expect him to respond effectively to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/ba1a34-ar-ba1a34b.pkl. "
BLCA,5.0,,excluded,NR,"In a female patient with bladder urothelial carcinoma, whose kidney biopsy showed specific mRNA TPM expression profiling of the tumor immune microenvironment and a tumor mutational burden of 5.0, how likely is she to respond to atezolizumab therapy?","In a female patient with bladder urothelial carcinoma, whose kidney biopsy showed specific mRNA TPM expression profiling of the tumor immune microenvironment and a tumor mutational burden of 5.0, how likely is she to respond to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/ba7176-ar-ba7176a.pkl. "
BLCA,7.0,0.745098039,desert,NR,"In a female patient with bladder urothelial carcinoma whose tumor immune microenvironment was assessed via mRNA TPM expression from a bladder biopsy and who has a tumor mutational burden of 7.0, what is the likelihood that she will respond to atezolizumab therapy?","In a female patient with bladder urothelial carcinoma whose tumor immune microenvironment was assessed via mRNA TPM expression from a bladder biopsy and who has a tumor mutational burden of 7.0, what is the likelihood that she will respond to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/bc8dc3-ar-bc8dc3a.pkl. "
BLCA,,,excluded,NR,"I am evaluating a male patient with bladder urothelial carcinoma. His bladder biopsy included an mRNA TPM expression analysis to characterize the tumor immune microenvironment, but his tumor mutational burden (TMB) is reported as 'nan.' Given this information, how likely is it that he will respond to atezolizumab therapy?","I am evaluating a male patient with bladder urothelial carcinoma. His bladder biopsy included an mRNA TPM expression analysis to characterize the tumor immune microenvironment, but his tumor mutational burden (TMB) is reported as 'nan.' Given this information, how likely is it that he will respond to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/bcb07b-ar-bcb07ba.pkl. "
BLCA,9.0,,desert,NR,"I have a male patient with bladder urothelial carcinoma whose biopsy revealed mRNA TPM expression profiling of the tumor immune microenvironment and a tumor mutational burden of 9.0. Based on these findings, would you expect the patient to have a favorable response to atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma whose biopsy revealed mRNA TPM expression profiling of the tumor immune microenvironment and a tumor mutational burden of 9.0. Based on these findings, would you expect the patient to have a favorable response to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/bcbc79-ar-bcbc795.pkl. "
BLCA,20.0,1.254901961,inflamed,NR,"I have a female patient with bladder urothelial carcinoma whose mRNA TPM expression was assessed from a bladder biopsy to characterize the tumor immune microenvironment. With a tumor mutational burden of 20.0, would you anticipate that this patient is likely to respond to Atezolizumab therapy?","I have a female patient with bladder urothelial carcinoma whose mRNA TPM expression was assessed from a bladder biopsy to characterize the tumor immune microenvironment. With a tumor mutational burden of 20.0, would you anticipate that this patient is likely to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/bda79f-ar-bda79f9.pkl. "
BLCA,10.0,0.784313725,excluded,NR,"I have a female patient with bladder urothelial carcinoma who underwent a lymph node biopsy with mRNA TPM expression analysis to evaluate the tumor immune microenvironment, and her tumor mutational burden is 10.0. Given these findings, how likely is she to respond to atezolizumab therapy?","I have a female patient with bladder urothelial carcinoma who underwent a lymph node biopsy with mRNA TPM expression analysis to evaluate the tumor immune microenvironment, and her tumor mutational burden is 10.0. Given these findings, how likely is she to respond to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/be83ea-ar-be83eae.pkl. "
BLCA,35.0,3.745098039,excluded,R,"For a male patient with bladder urothelial carcinoma who has a tumor mutational burden of 35.0 based on mRNA TPM expression analysis from a bladder biopsy, can we expect a favorable response to treatment with atezolizumab?","For a male patient with bladder urothelial carcinoma who has a tumor mutational burden of 35.0 based on mRNA TPM expression analysis from a bladder biopsy, can we expect a favorable response to treatment with atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/bf1a3a-ar-bf1a3ae.pkl. "
BLCA,6.0,1.450980392,excluded,NR,"For a female patient with bladder urothelial carcinoma, whose tumor mRNA TPM expression was measured from a bladder biopsy to assess the immune microenvironment and who has a tumor mutational burden of 6.0, would she be expected to respond well to Atezolizumab therapy?","For a female patient with bladder urothelial carcinoma, whose tumor mRNA TPM expression was measured from a bladder biopsy to assess the immune microenvironment and who has a tumor mutational burden of 6.0, would she be expected to respond well to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/bfdffb-ar-bfdffb9.pkl. "
BLCA,3.0,0.294117647,desert,NR,"For a female patient with bladder urothelial carcinoma who has a tumor mutational burden of 3.0 and an mRNA TPM expression profile from a bladder biopsy used to evaluate the tumor immune microenvironment, is there evidence to suggest that treatment with atezolizumab would be effective?","For a female patient with bladder urothelial carcinoma who has a tumor mutational burden of 3.0 and an mRNA TPM expression profile from a bladder biopsy used to evaluate the tumor immune microenvironment, is there evidence to suggest that treatment with atezolizumab would be effective?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/c0d625-ar-c0d625a.pkl. "
BLCA,5.0,1.176470588,desert,NR,"A male patient with bladder urothelial carcinoma has undergone a bladder biopsy that provided mRNA TPM expression data, and his tumor mutational burden is 5.0. Given these findings, can we expect a favorable response to atezolizumab therapy?","A male patient with bladder urothelial carcinoma has undergone a bladder biopsy that provided mRNA TPM expression data, and his tumor mutational burden is 5.0. Given these findings, can we expect a favorable response to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/c0da5d-ar-c0da5d4.pkl. "
BLCA,5.0,0.960784314,desert,NR,"Given a patient with bladder urothelial carcinoma whose tumor mRNA TPM expression was evaluated via nanobiopsy to assess the tumor immune microenvironment, and a tumor mutational burden of 5.0, would this patient likely benefit from Atezolizumab therapy?","Given a patient with bladder urothelial carcinoma whose tumor mRNA TPM expression was evaluated via nanobiopsy to assess the tumor immune microenvironment, and a tumor mutational burden of 5.0, would this patient likely benefit from Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/c0ef41-ar-c0ef41a.pkl. "
BLCA,5.0,1.098039216,excluded,R,"For a male patient with bladder urothelial carcinoma whose bladder biopsy mRNA TPM expression analysis indicates a tumor mutational burden of 5.0, how likely is it that he will respond to Atezolizumab therapy?","For a male patient with bladder urothelial carcinoma whose bladder biopsy mRNA TPM expression analysis indicates a tumor mutational burden of 5.0, how likely is it that he will respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/c1251c-ar-c1251c7.pkl. "
BLCA,5.0,1.411764706,excluded,R,"I have a male patient with bladder urothelial carcinoma whose tumor immune microenvironment was evaluated using mRNA TPM expression analysis from a kidney biopsy. With a tumor mutational burden of 5.0 mutations per megabase, would you expect a favorable response to Atezolizumab?","I have a male patient with bladder urothelial carcinoma whose tumor immune microenvironment was evaluated using mRNA TPM expression analysis from a kidney biopsy. With a tumor mutational burden of 5.0 mutations per megabase, would you expect a favorable response to Atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/c1b27b-ar-c1b27bc.pkl. "
BLCA,,,excluded,R,"In a patient with bladder urothelial carcinoma, mRNA TPM expression was measured from a bladder biopsy to evaluate the tumor immune microenvironment, and the tumor mutational burden is not available. Given these factors, would you expect a favorable response to atezolizumab therapy?","In a patient with bladder urothelial carcinoma, mRNA TPM expression was measured from a bladder biopsy to evaluate the tumor immune microenvironment, and the tumor mutational burden is not available. Given these factors, would you expect a favorable response to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/c2a182-ar-c2a1820.pkl. "
BLCA,3.0,0.196078431,desert,NR,"For a male patient with bladder urothelial carcinoma who has undergone a bladder biopsy with mRNA TPM expression analysis of the tumor immune microenvironment and who has a tumor mutational burden of 3.0, would you expect him to respond favorably to atezolizumab therapy?","For a male patient with bladder urothelial carcinoma who has undergone a bladder biopsy with mRNA TPM expression analysis of the tumor immune microenvironment and who has a tumor mutational burden of 3.0, would you expect him to respond favorably to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/c57ead-ar-c57eadb.pkl. "
BLCA,10.0,,desert,NR,"A male patient with bladder urothelial carcinoma (BLCA) underwent a ureter biopsy for mRNA TPM expression profiling to evaluate the tumor immune microenvironment, and his tumor has a mutational burden (TMB) of 10.0. Considering these findings, what is the likelihood of a favorable response to Atezolizumab therapy?","A male patient with bladder urothelial carcinoma (BLCA) underwent a ureter biopsy for mRNA TPM expression profiling to evaluate the tumor immune microenvironment, and his tumor has a mutational burden (TMB) of 10.0. Considering these findings, what is the likelihood of a favorable response to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/c69253-ar-c692536.pkl. "
BLCA,3.0,0.450980392,excluded,NR,"For a patient with bladder urothelial carcinoma who has undergone a lymph node biopsy for mRNA TPM expression profiling of the tumor immune microenvironment and exhibits a tumor mutational burden of 3.0, is treatment with Atezolizumab likely to be effective?","For a patient with bladder urothelial carcinoma who has undergone a lymph node biopsy for mRNA TPM expression profiling of the tumor immune microenvironment and exhibits a tumor mutational burden of 3.0, is treatment with Atezolizumab likely to be effective?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/c6eff0-ar-c6eff05.pkl. "
BLCA,3.0,0.607843137,inflamed,R,"In a patient with bladder urothelial carcinoma who has a tumor mutational burden of 3.0 and mRNA TPM expression profiles from a bladder biopsy assessing the tumor immune microenvironment, how likely is it that the patient will respond to Atezolizumab therapy?","In a patient with bladder urothelial carcinoma who has a tumor mutational burden of 3.0 and mRNA TPM expression profiles from a bladder biopsy assessing the tumor immune microenvironment, how likely is it that the patient will respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/c919ae-ar-c919aeb.pkl. "
BLCA,11.0,1.352941176,inflamed,NR,"In a female patient with bladder urothelial carcinoma who has a tumor mutational burden of 11.0 and mRNA TPM expression data from a lung biopsy evaluating the tumor immune microenvironment, how likely is she to respond to Atezolizumab therapy?","In a female patient with bladder urothelial carcinoma who has a tumor mutational burden of 11.0 and mRNA TPM expression data from a lung biopsy evaluating the tumor immune microenvironment, how likely is she to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/cabb6d-ar-cabb6d5.pkl. "
BLCA,,0.843137255,desert,NR,"In a patient with bladder urothelial carcinoma, mRNA TPM expression from a lymph node biopsy was evaluated to characterize the tumor immune microenvironment, and tumor mutational burden data is unavailable. Given this information, what is the likelihood of a favorable response to Atezolizumab therapy?","In a patient with bladder urothelial carcinoma, mRNA TPM expression from a lymph node biopsy was evaluated to characterize the tumor immune microenvironment, and tumor mutational burden data is unavailable. Given this information, what is the likelihood of a favorable response to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/cb132b-ar-cb132b0.pkl. "
BLCA,,,,NR,"In a male patient with bladder urothelial carcinoma, mRNA TPM expression was assessed from a liver biopsy to evaluate the tumor immune microenvironment, but the tumor mutational burden is not available. Based on these findings, what is the likelihood that the patient will respond to atezolizumab therapy?","In a male patient with bladder urothelial carcinoma, mRNA TPM expression was assessed from a liver biopsy to evaluate the tumor immune microenvironment, but the tumor mutational burden is not available. Based on these findings, what is the likelihood that the patient will respond to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/cc4675-ar-cc4675f.pkl. "
BLCA,26.0,4.960784314,inflamed,R,"For a female patient with bladder urothelial carcinoma who underwent a ureter biopsy with mRNA TPM expression measured to evaluate the tumor immune microenvironment and has a tumor mutational burden of 26, what are the chances that she would respond to Atezolizumab therapy?","For a female patient with bladder urothelial carcinoma who underwent a ureter biopsy with mRNA TPM expression measured to evaluate the tumor immune microenvironment and has a tumor mutational burden of 26, what are the chances that she would respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/cc7a42-ar-cc7a42d.pkl. "
BLCA,14.0,0.843137255,inflamed,NR,"A patient with bladder urothelial carcinoma has undergone mRNA TPM expression analysis from a bladder biopsy to evaluate the tumor immune microenvironment and has a tumor mutational burden of 14.0. Based on these findings, what is the likelihood that the patient will respond to Atezolizumab therapy?","A patient with bladder urothelial carcinoma has undergone mRNA TPM expression analysis from a bladder biopsy to evaluate the tumor immune microenvironment and has a tumor mutational burden of 14.0. Based on these findings, what is the likelihood that the patient will respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/ce39dd-ar-ce39dd7.pkl. "
BLCA,,,excluded,NR,"In a male patient with bladder urothelial carcinoma, mRNA TPM expression was measured from a lung biopsy to evaluate the tumor immune microenvironment, and the reported tumor mutational burden is ""nan."" Given these findings, would treatment with atezolizumab be expected to be effective?","In a male patient with bladder urothelial carcinoma, mRNA TPM expression was measured from a lung biopsy to evaluate the tumor immune microenvironment, and the reported tumor mutational burden is ""nan."" Given these findings, would treatment with atezolizumab be expected to be effective?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/cf018f-ar-cf018fe.pkl. "
BLCA,4.0,0.764705882,desert,R,"In a female patient with bladder urothelial carcinoma who has a tumor mutational burden of 4.0 and mRNA TPM expression data from a ureter biopsy assessing the tumor immune microenvironment, how likely is she to respond to Atezolizumab treatment?","In a female patient with bladder urothelial carcinoma who has a tumor mutational burden of 4.0 and mRNA TPM expression data from a ureter biopsy assessing the tumor immune microenvironment, how likely is she to respond to Atezolizumab treatment?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d02712-ar-d027124.pkl. "
BLCA,3.0,0.607843137,excluded,NR,"For a male patient with bladder urothelial carcinoma and a tumor mutational burden of 3.0, whose bladder biopsy mRNA TPM expression analysis has characterized the tumor immune microenvironment, how likely is it that he will respond to treatment with Atezolizumab?","For a male patient with bladder urothelial carcinoma and a tumor mutational burden of 3.0, whose bladder biopsy mRNA TPM expression analysis has characterized the tumor immune microenvironment, how likely is it that he will respond to treatment with Atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d135d5-ar-d135d58.pkl. "
BLCA,22.0,,,NR,"In a male patient with bladder urothelial carcinoma, a biopsy revealed mRNA TPM expression profiling of the tumor immune microenvironment and a tumor mutational burden of 22. Given these findings, would treatment with atezolizumab be expected to be effective?","In a male patient with bladder urothelial carcinoma, a biopsy revealed mRNA TPM expression profiling of the tumor immune microenvironment and a tumor mutational burden of 22. Given these findings, would treatment with atezolizumab be expected to be effective?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d1bd63-ar-d1bd637.pkl. "
BLCA,,,,NR,In a male patient with bladder urothelial carcinoma evaluated via mRNA TPM expression analysis from a bladder biopsy to characterize the tumor immune microenvironment—and with the tumor mutational burden not available—how predictive are these factors of a response to Atezolizumab therapy?,In a male patient with bladder urothelial carcinoma evaluated via mRNA TPM expression analysis from a bladder biopsy to characterize the tumor immune microenvironment—and with the tumor mutational burden not available—how predictive are these factors of a response to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d215b5-ar-d215b50.pkl. 
BLCA,3.0,0.490196078,desert,NR,"For a female patient with bladder urothelial carcinoma who has a tumor mutational burden of 3.0 and mRNA TPM expression data from a lymph node biopsy assessing the tumor immune microenvironment, how likely is she to respond to treatment with atezolizumab?","For a female patient with bladder urothelial carcinoma who has a tumor mutational burden of 3.0 and mRNA TPM expression data from a lymph node biopsy assessing the tumor immune microenvironment, how likely is she to respond to treatment with atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d2492b-ar-d2492b2.pkl. "
BLCA,62.0,10.01960784,excluded,R,"In a male patient with bladder urothelial carcinoma, where mRNA TPM expression profiling from a kidney biopsy was used to assess the tumor immune microenvironment and the tumor mutational burden is 62.0, would you expect a favorable response to Atezolizumab treatment?","In a male patient with bladder urothelial carcinoma, where mRNA TPM expression profiling from a kidney biopsy was used to assess the tumor immune microenvironment and the tumor mutational burden is 62.0, would you expect a favorable response to Atezolizumab treatment?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d35318-ar-d353181.pkl. "
BLCA,14.0,0.784313725,excluded,R,"For a male patient with bladder urothelial carcinoma who has a tumor mutational burden of 14.0 and mRNA TPM expression data from a separate biopsy assessing the tumor immune microenvironment, how likely is the patient to respond to atezolizumab therapy based on these biomarkers?","For a male patient with bladder urothelial carcinoma who has a tumor mutational burden of 14.0 and mRNA TPM expression data from a separate biopsy assessing the tumor immune microenvironment, how likely is the patient to respond to atezolizumab therapy based on these biomarkers?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d36012-ar-d360128.pkl. "
BLCA,7.0,1.568627451,excluded,R,"For a patient with bladder urothelial carcinoma who has undergone lymph node biopsy with mRNA TPM expression profiling of the tumor immune microenvironment and exhibits a TMB of 7.0, how likely is it that treatment with Atezolizumab will be effective?","For a patient with bladder urothelial carcinoma who has undergone lymph node biopsy with mRNA TPM expression profiling of the tumor immune microenvironment and exhibits a TMB of 7.0, how likely is it that treatment with Atezolizumab will be effective?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d3bd67-ar-d3bd679.pkl. "
BLCA,15.0,1.882352941,inflamed,R,"I am evaluating a male patient with bladder urothelial carcinoma whose tumor immune microenvironment has been characterized by mRNA TPM expression from a bladder biopsy. With a tumor mutational burden of 15.0, do these findings suggest that he is likely to respond to Atezolizumab therapy?","I am evaluating a male patient with bladder urothelial carcinoma whose tumor immune microenvironment has been characterized by mRNA TPM expression from a bladder biopsy. With a tumor mutational burden of 15.0, do these findings suggest that he is likely to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d43f89-ar-d43f893.pkl. "
BLCA,5.0,0.529411765,excluded,NR,"In a male patient with bladder urothelial carcinoma whose tumor immune microenvironment was assessed using mRNA TPM expression from a kidney biopsy and who has a tumor mutational burden of 5.0, would you expect Atezolizumab to be an effective treatment option?","In a male patient with bladder urothelial carcinoma whose tumor immune microenvironment was assessed using mRNA TPM expression from a kidney biopsy and who has a tumor mutational burden of 5.0, would you expect Atezolizumab to be an effective treatment option?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d4c083-ar-d4c0837.pkl. "
BLCA,,0.196078431,inflamed,NR,"I have a male patient with bladder urothelial carcinoma whose mRNA TPM expression was measured from a bladder biopsy to assess the tumor immune microenvironment. The tumor mutational burden result is not available (""nan""). Given these findings, what is the likelihood that he would respond to treatment with atezolizumab?","I have a male patient with bladder urothelial carcinoma whose mRNA TPM expression was measured from a bladder biopsy to assess the tumor immune microenvironment. The tumor mutational burden result is not available (""nan""). Given these findings, what is the likelihood that he would respond to treatment with atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d636e3-ar-d636e34.pkl. "
BLCA,,,excluded,NR,"We have a female patient with bladder urothelial carcinoma who underwent a ureteral biopsy, and her mRNA TPM expression was analyzed to assess the tumor immune microenvironment. However, her tumor mutational burden (TMB) is reported as ""nan."" Given these factors, what is the likelihood that she will respond favorably to treatment with Atezolizumab?","We have a female patient with bladder urothelial carcinoma who underwent a ureteral biopsy, and her mRNA TPM expression was analyzed to assess the tumor immune microenvironment. However, her tumor mutational burden (TMB) is reported as ""nan."" Given these factors, what is the likelihood that she will respond favorably to treatment with Atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d697ba-ar-d697ba7.pkl. "
BLCA,24.0,,inflamed,R,"Given a patient with bladder urothelial carcinoma whose bladder biopsy shows mRNA TPM expression profiling and who has a tumor mutational burden of 24.0, is treatment with atezolizumab likely to be effective?","Given a patient with bladder urothelial carcinoma whose bladder biopsy shows mRNA TPM expression profiling and who has a tumor mutational burden of 24.0, is treatment with atezolizumab likely to be effective?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d7d57e-ar-d7d57ee.pkl. "
BLCA,,1.411764706,desert,NR,For a male patient with bladder urothelial carcinoma who has undergone a bladder biopsy with mRNA TPM expression analysis to evaluate the tumor immune microenvironment—and with the tumor mutational burden currently unavailable—would these factors suggest that Atezolizumab is likely to be effective?,For a male patient with bladder urothelial carcinoma who has undergone a bladder biopsy with mRNA TPM expression analysis to evaluate the tumor immune microenvironment—and with the tumor mutational burden currently unavailable—would these factors suggest that Atezolizumab is likely to be effective?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d86389-ar-d86389d.pkl. 
BLCA,8.0,0.725490196,desert,NR,"For a patient with bladder urothelial carcinoma whose ureter biopsy mRNA TPM expression reflects the tumor immune microenvironment and has a tumor mutational burden of 8.0, would you consider Atezolizumab a likely effective treatment option?","For a patient with bladder urothelial carcinoma whose ureter biopsy mRNA TPM expression reflects the tumor immune microenvironment and has a tumor mutational burden of 8.0, would you consider Atezolizumab a likely effective treatment option?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d98bac-ar-d98bac0.pkl. "
BLCA,4.0,0.274509804,,NR,"In a male patient with bladder urothelial carcinoma, whose tumor immune microenvironment was evaluated using mRNA TPM expression from a kidney biopsy and who has a TMB of 4.0, is treatment with Atezolizumab likely to be effective?","In a male patient with bladder urothelial carcinoma, whose tumor immune microenvironment was evaluated using mRNA TPM expression from a kidney biopsy and who has a TMB of 4.0, is treatment with Atezolizumab likely to be effective?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/da4d89-ar-da4d892.pkl. "
BLCA,14.0,2.921568627,excluded,NR,"I have a patient with bladder urothelial carcinoma whose tumor biopsy revealed an mRNA TPM expression profile assessing the immune microenvironment, and the tumor mutation burden is 14.0. Based on these findings, is the patient likely to respond favorably to atezolizumab?","I have a patient with bladder urothelial carcinoma whose tumor biopsy revealed an mRNA TPM expression profile assessing the immune microenvironment, and the tumor mutation burden is 14.0. Based on these findings, is the patient likely to respond favorably to atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/dab9ca-ar-dab9ca8.pkl. "
BLCA,5.0,0.666666667,excluded,NR,"For a male patient with bladder urothelial carcinoma whose bladder biopsy shows mRNA TPM expression indicative of the tumor immune microenvironment and a tumor mutational burden (TMB) of 5.0, would treatment with atezolizumab be expected to result in a favorable therapeutic response?","For a male patient with bladder urothelial carcinoma whose bladder biopsy shows mRNA TPM expression indicative of the tumor immune microenvironment and a tumor mutational burden (TMB) of 5.0, would treatment with atezolizumab be expected to result in a favorable therapeutic response?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/dad5c2-ar-dad5c29.pkl. "
BLCA,10.0,0.509803922,excluded,NR,"For a male patient with bladder urothelial carcinoma who has a tumor mutational burden (TMB) of 10.0 and mRNA TPM expression data from a bladder biopsy assessing the tumor immune microenvironment, how likely is it that he will respond to Atezolizumab therapy?","For a male patient with bladder urothelial carcinoma who has a tumor mutational burden (TMB) of 10.0 and mRNA TPM expression data from a bladder biopsy assessing the tumor immune microenvironment, how likely is it that he will respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/db3f50-ar-db3f50c.pkl. "
BLCA,,1.431372549,excluded,NR,For a male patient with bladder urothelial carcinoma who underwent kidney biopsy for mRNA TPM expression analysis to assess the tumor immune microenvironment—and with tumor mutational burden data unavailable—can we expect a favorable response to atezolizumab therapy?,For a male patient with bladder urothelial carcinoma who underwent kidney biopsy for mRNA TPM expression analysis to assess the tumor immune microenvironment—and with tumor mutational burden data unavailable—can we expect a favorable response to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/dcae54-ar-dcae54f.pkl. 
BLCA,,,,NR,"In a male patient with bladder urothelial carcinoma (BLCA), mRNA expression profiles were obtained from a lymph node biopsy to evaluate the tumor immune microenvironment, and the tumor mutational burden (TMB) is reported as 'nan.' Given these findings, what can be inferred about the likelihood of response to atezolizumab?","In a male patient with bladder urothelial carcinoma (BLCA), mRNA expression profiles were obtained from a lymph node biopsy to evaluate the tumor immune microenvironment, and the tumor mutational burden (TMB) is reported as 'nan.' Given these findings, what can be inferred about the likelihood of response to atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/dee101-ar-dee1011.pkl. "
BLCA,19.0,3.235294118,inflamed,NR,"I have a male patient with bladder urothelial carcinoma whose tumor mRNA TPM expression was measured from a bladder biopsy to assess the tumor immune microenvironment, and the tumor mutational burden is 19.0. Based on these findings, what is the likelihood that he will respond favorably to Atezolizumab?","I have a male patient with bladder urothelial carcinoma whose tumor mRNA TPM expression was measured from a bladder biopsy to assess the tumor immune microenvironment, and the tumor mutational burden is 19.0. Based on these findings, what is the likelihood that he will respond favorably to Atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/df3e42-ar-df3e42c.pkl. "
BLCA,5.0,0.549019608,desert,NR,"For a female patient with bladder urothelial carcinoma who underwent a ureter biopsy to assess the tumor immune microenvironment using mRNA TPM expression, and with a tumor mutational burden of 5.0, what is the likelihood that Atezolizumab would be effective as a treatment option?","For a female patient with bladder urothelial carcinoma who underwent a ureter biopsy to assess the tumor immune microenvironment using mRNA TPM expression, and with a tumor mutational burden of 5.0, what is the likelihood that Atezolizumab would be effective as a treatment option?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e07c45-ar-e07c456.pkl. "
BLCA,2.0,,excluded,NR,"In a female patient with bladder urothelial carcinoma, where mRNA TPM expression analysis from a bladder biopsy has been performed to assess the tumor immune microenvironment and the tumor mutational burden is 2.0, how likely is it that she will respond to Atezolizumab therapy?","In a female patient with bladder urothelial carcinoma, where mRNA TPM expression analysis from a bladder biopsy has been performed to assess the tumor immune microenvironment and the tumor mutational burden is 2.0, how likely is it that she will respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e0c49e-ar-e0c49ea.pkl. "
BLCA,14.0,2.274509804,inflamed,R,"I have a male patient with bladder urothelial carcinoma whose bladder biopsy revealed an mRNA TPM expression profile assessing the tumor immune microenvironment and a tumor mutational burden of 14.0. Based on these findings, is he likely to respond well to Atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma whose bladder biopsy revealed an mRNA TPM expression profile assessing the tumor immune microenvironment and a tumor mutational burden of 14.0. Based on these findings, is he likely to respond well to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e1eb5d-ar-e1eb5d9.pkl. "
BLCA,17.0,0.862745098,inflamed,NR,"My patient is a female with bladder urothelial carcinoma. We assessed the tumor immune microenvironment using mRNA TPM expression from a nanobiopsy, and her tumor mutational burden is 17.0. Based on these findings, might she be a good candidate for Atezolizumab therapy?","My patient is a female with bladder urothelial carcinoma. We assessed the tumor immune microenvironment using mRNA TPM expression from a nanobiopsy, and her tumor mutational burden is 17.0. Based on these findings, might she be a good candidate for Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e3210d-ar-e3210d3.pkl. "
BLCA,,,,NR,"I have a patient with bladder urothelial carcinoma whose bladder biopsy shows mRNA TPM expression data for the tumor immune microenvironment, but the tumor mutational burden is not available (reported as ""nan""). Given these findings, what is the likelihood that this patient will respond to Atezolizumab therapy?","I have a patient with bladder urothelial carcinoma whose bladder biopsy shows mRNA TPM expression data for the tumor immune microenvironment, but the tumor mutational burden is not available (reported as ""nan""). Given these findings, what is the likelihood that this patient will respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e3d426-ar-e3d4266.pkl. "
BLCA,6.0,0.470588235,excluded,NR,"In a male patient with bladder urothelial carcinoma whose tumor biopsy revealed mRNA TPM expression indicative of the tumor immune microenvironment and a tumor mutational burden of 6.0, is treatment with atezolizumab likely to be effective?","In a male patient with bladder urothelial carcinoma whose tumor biopsy revealed mRNA TPM expression indicative of the tumor immune microenvironment and a tumor mutational burden of 6.0, is treatment with atezolizumab likely to be effective?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e41b1e-ar-e41b1e7.pkl. "
BLCA,9.0,2.176470588,desert,R,"In a female patient with bladder urothelial carcinoma, mRNA expression (TPM) was assessed from a bladder biopsy to evaluate the tumor immune microenvironment, and the tumor mutational burden is 9.0. Given these findings, how likely is it that the patient will respond to Atezolizumab therapy?","In a female patient with bladder urothelial carcinoma, mRNA expression (TPM) was assessed from a bladder biopsy to evaluate the tumor immune microenvironment, and the tumor mutational burden is 9.0. Given these findings, how likely is it that the patient will respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e50d15-ar-e50d15f.pkl. "
BLCA,5.0,0.098039216,excluded,NR,"For a female patient with bladder urothelial carcinoma (BLCA), whose tumor immune microenvironment was assessed via mRNA TPM expression from a kidney biopsy, and who has a tumor mutational burden (TMB) of 5.0, how likely is a favorable response to Atezolizumab therapy?","For a female patient with bladder urothelial carcinoma (BLCA), whose tumor immune microenvironment was assessed via mRNA TPM expression from a kidney biopsy, and who has a tumor mutational burden (TMB) of 5.0, how likely is a favorable response to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e56c96-ar-e56c96c.pkl. "
BLCA,5.0,0.274509804,excluded,NR,"A  how does a male patient with bladder urothelial carcinoma, whose mRNA TPM expression was assessed via a liver biopsy to evaluate the tumor immune microenvironment and who has a tumor mutational burden of 5.0, likely respond to Atezolizumab therapy?","A  how does a male patient with bladder urothelial carcinoma, whose mRNA TPM expression was assessed via a liver biopsy to evaluate the tumor immune microenvironment and who has a tumor mutational burden of 5.0, likely respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e5bc41-ar-e5bc417.pkl. "
BLCA,,,desert,R,"I have a male patient with bladder urothelial carcinoma whose mRNA TPM expression was measured from a bladder biopsy to assess the tumor immune microenvironment, and his tumor mutational burden (TMB) data is not available. Given these considerations, how likely is it that he will respond to atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma whose mRNA TPM expression was measured from a bladder biopsy to assess the tumor immune microenvironment, and his tumor mutational burden (TMB) data is not available. Given these considerations, how likely is it that he will respond to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e71235-ar-e712352.pkl. "
BLCA,,,,NR,"I have a male patient with bladder urothelial carcinoma who underwent a kidney biopsy to profile mRNA TPM expression in order to evaluate the tumor immune microenvironment. Although the tumor mutational burden data is not available, would the molecular findings support a favorable response to Atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma who underwent a kidney biopsy to profile mRNA TPM expression in order to evaluate the tumor immune microenvironment. Although the tumor mutational burden data is not available, would the molecular findings support a favorable response to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e7bcab-ar-e7bcab0.pkl. "
BLCA,7.0,1.37254902,inflamed,NR,"For a male patient with bladder urothelial carcinoma who underwent a kidney biopsy for mRNA TPM expression analysis of the tumor immune microenvironment and has a tumor mutational burden of 7.0, can we anticipate a favorable response to Atezolizumab therapy?","For a male patient with bladder urothelial carcinoma who underwent a kidney biopsy for mRNA TPM expression analysis of the tumor immune microenvironment and has a tumor mutational burden of 7.0, can we anticipate a favorable response to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e7bf6c-ar-e7bf6c0.pkl. "
BLCA,1.0,0.196078431,inflamed,NR,"In a male patient with bladder urothelial carcinoma (BLCA) whose tumor biopsy yielded mRNA TPM expression data for assessment of the immune microenvironment and a tumor mutational burden (TMB) of 1.0, would treatment with atezolizumab be likely to elicit a favorable response?","In a male patient with bladder urothelial carcinoma (BLCA) whose tumor biopsy yielded mRNA TPM expression data for assessment of the immune microenvironment and a tumor mutational burden (TMB) of 1.0, would treatment with atezolizumab be likely to elicit a favorable response?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e7e4f7-ar-e7e4f7c.pkl. "
BLCA,,,excluded,NR,"In a patient with bladder urothelial carcinoma evaluated via mRNA TPM expression from a bladder biopsy and with an indeterminate (nan) tumor mutational burden, how likely is it that the patient will respond to Atezolizumab therapy?","In a patient with bladder urothelial carcinoma evaluated via mRNA TPM expression from a bladder biopsy and with an indeterminate (nan) tumor mutational burden, how likely is it that the patient will respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e9475f-ar-e9475f7.pkl. "
BLCA,6.0,1.019607843,excluded,NR,"In a male patient with bladder urothelial carcinoma, mRNA TPM expression from a bladder biopsy has been used to evaluate the tumor immune microenvironment, and a TMB of 6.0 was recorded. How do these findings inform the likelihood of a favorable response to atezolizumab therapy?","In a male patient with bladder urothelial carcinoma, mRNA TPM expression from a bladder biopsy has been used to evaluate the tumor immune microenvironment, and a TMB of 6.0 was recorded. How do these findings inform the likelihood of a favorable response to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e94c30-ar-e94c30c.pkl. "
BLCA,3.0,0.705882353,excluded,NR,"For a female patient with bladder urothelial carcinoma whose bladder biopsy reveals specific mRNA TPM expression and a tumor mutational burden of 3.0, what is the likelihood of a favorable response to Atezolizumab therapy?","For a female patient with bladder urothelial carcinoma whose bladder biopsy reveals specific mRNA TPM expression and a tumor mutational burden of 3.0, what is the likelihood of a favorable response to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e97af0-ar-e97af0f.pkl. "
BLCA,7.0,1.333333333,desert,NR,"I have a male patient with bladder urothelial carcinoma whose tumor mutational burden is 7.0. His bladder biopsy mRNA TPM expression was evaluated to assess the tumor immune microenvironment. Based on these factors, how likely is he to respond to Atezolizumab therapy?","I have a male patient with bladder urothelial carcinoma whose tumor mutational burden is 7.0. His bladder biopsy mRNA TPM expression was evaluated to assess the tumor immune microenvironment. Based on these factors, how likely is he to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e9ae8b-ar-e9ae8be.pkl. "
BLCA,14.0,2.764705882,inflamed,R,"For a male patient with bladder urothelial carcinoma whose bladder biopsy indicates specific mRNA TPM expression profiles reflecting the tumor immune microenvironment and who exhibits a tumor mutational burden of 14.0, how likely is he to respond to Atezolizumab therapy?","For a male patient with bladder urothelial carcinoma whose bladder biopsy indicates specific mRNA TPM expression profiles reflecting the tumor immune microenvironment and who exhibits a tumor mutational burden of 14.0, how likely is he to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/eaa477-ar-eaa477a.pkl. "
BLCA,2.0,0.058823529,excluded,NR,"We have a male patient with bladder urothelial carcinoma whose tumor immune microenvironment was profiled using mRNA TPM expression from a kidney biopsy, and his tumor mutational burden is 2.0. Based on these findings, is he likely to benefit from treatment with Atezolizumab?","We have a male patient with bladder urothelial carcinoma whose tumor immune microenvironment was profiled using mRNA TPM expression from a kidney biopsy, and his tumor mutational burden is 2.0. Based on these findings, is he likely to benefit from treatment with Atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/eb2962-ar-eb29625.pkl. "
BLCA,,,,NR,"In a patient with bladder urothelial carcinoma, mRNA TPM expression from a bladder biopsy has been used to evaluate the tumor immune microenvironment, and the tumor mutational burden is reported as ""nan."" Given these factors, how likely is the patient to respond favorably to Atezolizumab therapy?","In a patient with bladder urothelial carcinoma, mRNA TPM expression from a bladder biopsy has been used to evaluate the tumor immune microenvironment, and the tumor mutational burden is reported as ""nan."" Given these factors, how likely is the patient to respond favorably to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/eb587a-ar-eb587a6.pkl. "
BLCA,,,,NR,"I have a male patient diagnosed with bladder urothelial carcinoma. A lymph node biopsy was performed, and mRNA TPM expression was analyzed to evaluate the tumor immune microenvironment. However, the tumor mutational burden was not assessable (NaN). Based on these factors, what is the likelihood that the patient would respond favorably to Atezolizumab therapy?","I have a male patient diagnosed with bladder urothelial carcinoma. A lymph node biopsy was performed, and mRNA TPM expression was analyzed to evaluate the tumor immune microenvironment. However, the tumor mutational burden was not assessable (NaN). Based on these factors, what is the likelihood that the patient would respond favorably to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/ee3844-ar-ee3844c.pkl. "
BLCA,1.0,0.039215686,inflamed,NR,"I have a patient with bladder urothelial carcinoma whose lung biopsy demonstrated an mRNA TPM expression profile of the tumor immune microenvironment and a tumor mutational burden of 1.0. Based on these findings, what is the likelihood that the patient would respond to Atezolizumab therapy?","I have a patient with bladder urothelial carcinoma whose lung biopsy demonstrated an mRNA TPM expression profile of the tumor immune microenvironment and a tumor mutational burden of 1.0. Based on these findings, what is the likelihood that the patient would respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/ef0e3d-ar-ef0e3d2.pkl. "
BLCA,14.0,,desert,NR,"In a male patient with bladder urothelial carcinoma whose ureter biopsy reveals mRNA TPM expression data detailing the tumor immune microenvironment and a tumor mutational burden of 14.0, how predictive are these factors of a favorable response to Atezolizumab?","In a male patient with bladder urothelial carcinoma whose ureter biopsy reveals mRNA TPM expression data detailing the tumor immune microenvironment and a tumor mutational burden of 14.0, how predictive are these factors of a favorable response to Atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/eff2ce-ar-eff2ce3.pkl. "
BLCA,14.0,1.098039216,inflamed,NR,"A male patient with bladder urothelial carcinoma has undergone a kidney biopsy, and mRNA TPM expression was evaluated to characterize the tumor immune microenvironment. His tumor mutational burden is 14.0. Based on these findings, what is his likelihood of responding to Atezolizumab?","A male patient with bladder urothelial carcinoma has undergone a kidney biopsy, and mRNA TPM expression was evaluated to characterize the tumor immune microenvironment. His tumor mutational burden is 14.0. Based on these findings, what is his likelihood of responding to Atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/f20b82-ar-f20b827.pkl. "
BLCA,9.0,,excluded,R,"For a patient with bladder urothelial carcinoma who has undergone a bladder biopsy showing mRNA TPM expression indicative of the tumor immune microenvironment and a tumor mutational burden of 9.0, how likely is a favorable response to atezolizumab therapy?","For a patient with bladder urothelial carcinoma who has undergone a bladder biopsy showing mRNA TPM expression indicative of the tumor immune microenvironment and a tumor mutational burden of 9.0, how likely is a favorable response to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/f275eb-ar-f275eb8.pkl. "
BLCA,8.0,,desert,NR,"In a male patient with bladder urothelial carcinoma, whose mRNA TPM expression profile from a bladder biopsy was used to evaluate the tumor immune microenvironment and with a tumor mutational burden of 8.0, how likely is he to benefit from treatment with Atezolizumab?","In a male patient with bladder urothelial carcinoma, whose mRNA TPM expression profile from a bladder biopsy was used to evaluate the tumor immune microenvironment and with a tumor mutational burden of 8.0, how likely is he to benefit from treatment with Atezolizumab?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/f28c01-ar-f28c015.pkl. "
BLCA,7.0,0.803921569,desert,NR,"In a female patient with bladder urothelial carcinoma, we assessed the tumor immune microenvironment using mRNA TPM expression from a bladder biopsy, and the tumor mutational burden was measured at 7.0. Based on these findings, how likely is the patient to respond favorably to Atezolizumab therapy?","In a female patient with bladder urothelial carcinoma, we assessed the tumor immune microenvironment using mRNA TPM expression from a bladder biopsy, and the tumor mutational burden was measured at 7.0. Based on these findings, how likely is the patient to respond favorably to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/f2aae1-ar-f2aae14.pkl. "
BLCA,4.0,,excluded,NR,"In a female patient with bladder urothelial carcinoma, whose kidney biopsy results show mRNA TPM expression indicative of the tumor immune microenvironment and a TMB of 4.0, how likely is she to respond to Atezolizumab therapy?","In a female patient with bladder urothelial carcinoma, whose kidney biopsy results show mRNA TPM expression indicative of the tumor immune microenvironment and a TMB of 4.0, how likely is she to respond to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/f3a9bc-ar-f3a9bce.pkl. "
BLCA,7.0,0.529411765,desert,NR,"In a male patient with bladder urothelial carcinoma, kidney biopsy analysis revealed mRNA TPM expression profiles to assess the tumor immune microenvironment, and the tumor mutational burden is 7.0. Considering these factors, is the patient likely to respond favorably to atezolizumab therapy?","In a male patient with bladder urothelial carcinoma, kidney biopsy analysis revealed mRNA TPM expression profiles to assess the tumor immune microenvironment, and the tumor mutational burden is 7.0. Considering these factors, is the patient likely to respond favorably to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/f82bbd-ar-f82bbdc.pkl. "
BLCA,,5.921568627,inflamed,R,"In a patient with bladder urothelial carcinoma whose biopsy yielded mRNA TPM expression data to assess the tumor immune microenvironment—and with a tumor mutational burden listed as ""nan""—can we reasonably expect a positive response to Atezolizumab therapy?","In a patient with bladder urothelial carcinoma whose biopsy yielded mRNA TPM expression data to assess the tumor immune microenvironment—and with a tumor mutational burden listed as ""nan""—can we reasonably expect a positive response to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/fb7aec-ar-fb7aec7.pkl. "
BLCA,5.0,,desert,NR,"In a male patient with bladder urothelial carcinoma, whose bladder biopsy revealed a specific mRNA TPM expression profile of the tumor immune microenvironment and a tumor mutational burden of 5.0, would treatment with Atezolizumab likely be effective?","In a male patient with bladder urothelial carcinoma, whose bladder biopsy revealed a specific mRNA TPM expression profile of the tumor immune microenvironment and a tumor mutational burden of 5.0, would treatment with Atezolizumab likely be effective?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/fd9476-ar-fd94761.pkl. "
BLCA,7.0,0.352941176,desert,NR,"A 65-year-old female patient with bladder urothelial carcinoma presents with a tumor mutational burden of 7.0 and mRNA TPM expression data (obtained from a bladder biopsy) that characterizes her tumor immune microenvironment. Based on these factors, what is the likelihood that she will respond favorably to Atezolizumab therapy?","A 65-year-old female patient with bladder urothelial carcinoma presents with a tumor mutational burden of 7.0 and mRNA TPM expression data (obtained from a bladder biopsy) that characterizes her tumor immune microenvironment. Based on these factors, what is the likelihood that she will respond favorably to Atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/fed609-ar-fed6099.pkl. "
BLCA,10.0,,desert,R,"For a male patient with bladder urothelial carcinoma who underwent mRNA TPM expression analysis from a biopsy to assess the tumor immune microenvironment and has a tumor mutational burden of 10.0, what is the likelihood of a favorable response to atezolizumab therapy?","For a male patient with bladder urothelial carcinoma who underwent mRNA TPM expression analysis from a biopsy to assess the tumor immune microenvironment and has a tumor mutational burden of 10.0, what is the likelihood of a favorable response to atezolizumab therapy?   The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/ffa5c7-ar-ffa5c7c.pkl. "
